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4Foreword
driven by an understanding of the strategic 
complexity of safeguarding children. Hopefully 
these sound strategic decisions will translate 
into an everyday working culture of professional 
curiosity and healthy scepticism, which we 
believe is essential in achieving the aim of 
protecting children from risk.
The new statistics are shocking. The scale of the 
issue is much larger than originally anticipated. 
Our report last year identified 23 incidents of 
ingestion and 17 child deaths between 2003 
and 2013; mortality data and hospitalisation 
data uncovered since show the real number of 
ingestions to be in the hundreds, and the number 
of deaths over 100. This more realistic estimation 
adds weight and urgency to the policy and 
practice recommendations in the original report; 
all of which still stand.
In any debate on this matter it’s important to 
keep sight of the fact that OST is an effective 
intervention with a substantial evidence base, 
both clinical and anecdotal; and the vast majority 
of those who use it do so safely and appropriately. 
Similarly, the majority of practitioners working 
to facilitate recovery and safeguard children are 
highly competent and passionate individuals, 
doing their best in a time of financial and 
structural constraint.
By the end of 2015, Adfam will have worked with 
multi-agency teams in 19 local authorities to 
develop joined-up and strategic approaches to 
better protect children whose parents or carers 
This report builds on our previous work, 
Medications in Drug Treatment: Tackling the risks 
to children, in considering the risks posed to 
children from substitute drugs prescribed to those 
struggling with opioid addiction – and proposing 
steps for minimising these risks. In the foreword 
to last year’s report I posed the question: ‘On a 
systemic level, are we doing all that we can to 
make sure these incidents don’t keep happening?’ 
I answered that question with a no; unfortunately, 
I must offer the same response this time around 
too. Of course, a year is not a long time to effect 
or even observe system change, and we have 
found some examples of encouraging practice and 
attitude at a local level.
It should go without saying that the death 
of any child is a human tragedy. Reports and 
investigations triggered by these tragedies, from 
the expansive Laming report following the murder 
of Victoria Climbié to the serious case reviews 
(SCRs) considered in this document, generally 
highlight a systemic and cultural failure from 
services which have not worked closely enough 
with each other in safeguarding vulnerable 
children.
There is an aphorism from the world of business 
management – ‘culture eats strategy for 
breakfast,’ which I believe has some relevance 
here. We have found some encouraging examples 
of new practice in local areas – for instance 
specialist midwifes in drug services, and joint-
working protocols between drug services and 
health visiting teams – which have clearly been 
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use OST medications. This has been extremely 
valuable in terms of both uncovering (and 
sharing) good practice, and together identifying 
areas for development. It is my hope that this 
practical but strategic work at a local level 
combined with the learning in this report will be a 
positive force in preventing some of these all too 
familiar future tragedies from occurring. 
Vivienne Evans OBE
Chief Executive
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• Evidence suggests that methadone is related to 
a higher mortality risk than buprenorphine
• A range of approaches are being taken by 
different local authorities to tackle the issue; 
yet, the continuation of SCRs where children 
have come to harm or died after ingesting OST 
medications means more needs to be done to 
effectively minimise and manage the risks to 
children posed by these medications. 
Medications in Drug Treatment: Tackling the Risks 
to Children was published by Adfam in April 2014.1  
The report examined cases where children had 
ingested medications prescribed for the treatment 
of opioid dependence, and made policy and practice 
recommendations to effectively safeguard children 
and minimise this risk. It revealed that in the period 
under review (2003-2013), 17 children died and a 
further six were seriously harmed after ingesting 
medications used in opioid substitution therapy 
(OST). A literature review was undertaken to seek 
available evidence and guidance on the issue, and 
the research was further informed by a number 
of consultations with practitioners from the drug 
treatment, health and social care sectors. The 
report was launched in Parliament the same month, 
with speakers including Adfam staff, Meg Munn 
MP, a GP and a member of a Local Safeguarding 
Children’s Board (LSCB). It was extensively promoted 
and publicised, and generated interest from both 
mainstream media outlets and sector press. The 
findings and recommendations of the report 
This ‘One Year On’ report expands upon the findings 
and recommendations of Adfam’s Medications 
in Drug Treatment: Tackling the risks to children, 
published in 2014, and further contributes to the 
debate on reducing the risks to children posed by 
prescribed medications used in opioid substitution 
therapy (OST).
Key findings:
• At least 110 persons aged 18 and under died 
from ingesting OST medications between 2003 
and 2013: 73 in England and Wales, and 37 in 
Scotland
• 107 of these were related to methadone, and 
three to buprenorphine 
• Of the 73 deaths in England and Wales, only 
seven resulted in a serious case review; meaning 
that an additional 66 deaths did not
• Hospitalisation statistics show that between 
2003 and 2014, at least 328 children were 
hospitalised in England due to methadone 
poisoning
• These data reveal that the majority of ingestions 
occur in adolescents, which is contrary to the 
bias towards younger children evident in serious 
case reviews 
• Since the original report’s publication, there 
have been three new serious case reviews (one 
awaiting publication) involving child ingestions 
of methadone; all of which involved children 
aged two and under, with the methadone 
prescribed to the mother
Introduction
 1 This will hereon in be referred to as the ‘original report’ or simply Medications 
in Drug Treatment
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Methodology
The information included in this report is taken from 
a range of sources:
 — A literature review provided updated 
information, data and further evidence
 — Data on the number of child deaths related to 
OST medications in England and Wales between 
2003 and 2013 was obtained from the Office for 
National Statistics (ONS)
 — Data on the number of child deaths related to 
OST medications in Northern Ireland between 
2003 and 20122 was obtained from the Northern 
Ireland Statistics and Research Agency (NISRA) 
 — Data on the number of child deaths related to 
OST medications in Scotland between 2003 and 
2013 was obtained from the National Records of 
Scotland (NRS) 
were much welcomed by practitioners across the 
board, who recognised a gap in knowledge and 
understanding of the issues, and were keen to 
improve practice on the ground.
Being determined to inspire and drive real change 
in policy and practice to significantly reduce 
the risks to children posed by OST medications, 
Adfam worked with four pilot local authorities in 
September 2015 to help them develop an action 
plan to enhance local practice, in keeping with the 
report’s recommendations. Following the pilot, this 
offer of training was extended to local authorities 
across the country. Progress on this work, based     
on the six recommendations of the original report,  
is set out later in this document. 
The purpose of this ‘One Year On’ report is to:
1. Describe and assess the progress made in 
implementing the recommendations of the 
original report, since its publication in April 
2014
2. Provide practice examples from services which 
have taken steps to address the issue
3. Provide updated information, data and evidence 
4. Outline Adfam’s progress in relation 
to disseminating and championing the 
recommendations of the original report
5. Provide a follow-up to the original report’s 
recommendations: expanding on the issues 
identified in the original report and making      
new recommendations to address them.
2  At the time of request, information on the number of child deaths for the 
year 2013 was unavailable.
3  In Wales, these are referred to as ‘child practice reviews,’ in Scotland, 
‘significant case reviews,’ and in Northern Ireland, ‘case management reviews.’ 
Despite differing terminology, the stipulations for conducting a review are 
identical i.e. that a child has died or come to serious harm and abuse or 
neglect are suspected or known to have been involved.
‘People need to be more 
aware of the dangers that 
methadone can pose to 
children.…This new report will 
play a valuable role in raising 
awareness of these cases, and 
pushing for a more effective 
approach to prevention.’ 
Meg Munn MP
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and limit the spread of blood-borne viruses.6  
The aim of this research is not to analyse or 
denounce the role of OST in treating opioid 
dependence generally: the evidence overwhelmingly 
shows that it is a valuable and effective tool in 
helping people overcome addiction. However, OST 
medications can present unique risks to children as 
compared to other drugs, including the chance of 
unsafe storage in sometimes chaotic households, 
the possible attractiveness of methadone to 
children,7 its real - albeit rare - use as a pacifier 
and its level of toxicity to children and opioid naïve 
adults, even in very small quantities.
The National Institute for Health and Care 
Excellence (NICE), in Technology Appraisal 114, 
stated that decisions on which medication to 
prescribe should ‘take account of the person’s 
lifestyle and family situation (for example whether 
they are considered chaotic and might put children 
and other opioid-naïve individuals living with them 
at risk),’ having recognised the high mortality risk 
associated with methadone, particularly in opioid-
naïve people.8 OST can be prescribed for take-home 
use or on a ‘supervised consumption’ regime, 
whereby service users9 are required to take the 
medication in the presence of a health professional, 
such as a pharmacist. Clinical guidance 
recommends that everyone should be placed on a 
supervised consumption regime for at least the first 
 — The full reports of the Blackpool ‘Child BT’ 
(2015) and the Oxfordshire ‘Child H’ (2014) 
serious case reviews (SCRs)3 were obtained from 
the respective LSCB websites
 — Media reports were sourced for other cases
 — Seven treatment services provided evidence 
and information on their current local and 
organisational policies and practice around OST 
and safeguarding, and of changes implemented 
in response to the findings of the original report
 — Four local authorities which had experienced 
a SCR responded to requests for information 
regarding the progress made following a SCR 
involving a child’s ingestion of OST.
Background
OST is a medical intervention whereby long-
acting opioid medications (primarily methadone 
or buprenorphine) are prescribed in replacement 
of illegal opioid drugs (such as heroin), with the 
purpose of reducing or preventing withdrawals, 
providing an opportunity to stabilise drug use and 
lifestyle, promoting a process of change in drug 
taking and risky behaviours, helping maintain contact 
and offering an opportunity for therapeutic work 
with a client.4 OST can enable people to become 
free from dependence on illicit substances, and 
provide opportunities to pursue recovery goals, 
such as employment or education. It has been found 
to decrease drug use and mortality, inspire high 
retention rates, improve quality of life,5 reduce crime 
4  Advisory Council on the Misuse of Drugs (2014) Time limiting opioid substitution therapy
5  Pihkala & Sandlund (2015) ‘Parenthood and opioid dependence,’ 6 Sub Abuse and Rehab 33
6  Reimer et. al. (2016) “The Impact of Misuse and Diversion of Opioid Substitution Treatment Medicines: Evidence Review and Expert Consensus,” 22(99) Eur 
Addict Res 106 (Available first online)
7  Methadone often comes as a green, sweet-tasting liquid.
8  National Institute for Health and Care Excellence (2007) Technology Appraisal 114: Methadone and buprenorphine for the management of opioid dependence
9  The terms ‘client’, ‘patient’ and ‘service user’ will be used interchangeably throughout.
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Key findings from the original report
1. OST has a rightful place in a recovery-
orientated treatment system, and the majority 
of people who need and use OST do so safely
2. OST medications can present risks to 
children that other prescription drugs do 
not i.e. toxicity in very small doses, possible 
attractiveness to children, chance of unsafe 
storage in chaotic households and the proven 
use of methadone as a pacifier
3. The risks to children posed by OST 
medications are not sufficiently managed and 
minimised in practice
4. Serious Case Reviews did not result in 
sustainable local improvements
5. There is a clear knowledge gap in relation to 
child ingestions of OST and the true number of 
incidents is unknown
6. Service users and professionals are sometimes 
not fully aware of the dangers that OST drugs 
can pose to children
7. Professionals should be supported to assess 
risk in families where parental substance 
use is a factor, and in embedding healthy 
scepticism and professional challenge into 
their practice
8. Methadone is involved in substantially more 
child ingestions than buprenorphine
9. Despite clinical guidelines, safeguarding 
concerns may not be sufficiently prioritised in 
three months of prescribing, with relaxation (i.e. 
a reduction in supervised doses and an increase 
in take-home prescriptions allowed) over a period 
of time, to reflect the client’s compliance with 
treatment.10
The Department of Health, in emphasising that 
prescribing arrangements should aim to reduce 
risks to children, has suggested that supervised 
consumption is the ‘best guarantee’ the medicine 
is used as directed, and advises against take-home 
doses where there are concerns over the safe 
storage of medications at home, ‘or potential 
risks to children.’11 Despite such unambiguous 
guidance, findings from the original report 
suggested that safeguarding children from the 
risks posed by OST medications was failing to be 
sufficiently prioritised and addressed in practice. 
10  Department of Health (2007) Drug misuse 
and dependence: UK Guidelines on Clinical 
Management
11  Ibid
Section one: 
Assessing impact,
measuring change
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To improve awareness of the risks to children 
associated with OST medications and share best 
practice, Adfam also presented the report’s findings 
and recommendations to over 400 professionals in 
drug treatment, health and social care, and others. 
This included:
 — Students at Winchester University, BSc Children, 
Youth and Community Studies programme
 — The London Drug and Alcohol Policy Forum
 — The Annual General Meeting of SPODA (a family 
support service in a local authority which has 
experienced cases of child ingestion)
 — Adfam’s North West Regional Forum for 
practitioners supporting families affected by 
drug and alcohol use
 — DrugScope’s annual conference 2014
 — Drugs & Alcohol Today conference 
 — Indivior (the report’s funders)
 — Staff in drug treatment, health and social care in 
seven different local authorities that contacted 
Adfam directly to request a presentation.
Evidence of local practice and changes to 
practice
One of the aims of this report is to examine how 
the risk of child ingestions of medications used 
in the treatment of opioid dependence is being 
addressed locally, with particular attention paid to 
the implementation of the recommendations of the 
original report. One of the aims of a SCR is to look 
at lessons that help prevent similar incidents in the 
future. Medications in Drug Treatment identified a 
missed opportunity; in that learning from cases was 
generally restricted to areas where a SCR had taken 
Following the launch of the report, the priority was 
to disseminate its findings and to build relationships 
with key organisations and individuals in the 
substance use, health and social care sectors, as 
well as national bodies, in order to embed and 
implement the recommendations. The report 
was widely disseminated at Adfam events and 
conferences, third party events and conferences and 
at meetings with practitioners and organisations. 
Strategic support was also sought in a number of 
ways:
 — The Association of Independent Local 
Safeguarding Children Board Chairs was 
contacted to draw their attention to the specific 
recommendation regarding the increase in 
drug service representation on LSCBs, and to 
secure strategic support generally. Contact 
was attempted several times. No response was 
received
 — A meeting between Adfam and Public Health 
England (PHE) was held to discuss how the 
report’s recommendations could be taken 
forward. PHE was supportive of the work and 
continue to be kept informed
 — Adfam contributed to the Advisory Council on 
the Misuse of Drugs (ACMD) inquiry into the 
diversion of medicines, the report of which is 
due to be published in late 2015
 — A submission to the Department of Health’s 
consultation to update the ‘Orange Book’ (or 
Drug misuse and dependence: UK Guidelines 
on Clinical Management) was made to highlight 
the findings and recommendations of the report. 
This is discussed in Section Four.
Section one: Assessing impact,
measuring change
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practice guidance and an assessment tool 
for health visitors working with parental 
substance use and an audit of referrals from 
the drug treatment provider to health visiting 
teams
 » SCR Area 4 provided an overview of local 
policy and practice
 — Two local authorities that had not experienced 
a SCR were prompted by Medications in Drug 
Treatment to compile briefings, and one 
developed an action plan  for local policy and 
joint-working as a result
 — An overview of local policy and practice was 
obtained from a local authority that used 
Bristol’s ‘Child K’ SCR as impetus for reviewing 
their own ways of working. It also provided 
an audit sheet, safeguarding checklist, safe 
storage guidance for service users, safeguarding 
guidance for practitioners, a patient safety 
agreement and safe storage box guidance 
 — A local treatment provider in Wales, which set 
up a working group in the aftermath of the 
report’s publication, submitted a pro forma letter 
sent to health visitors by the drug treatment 
provider, and a checklist used by the provider to 
assess suitability for take-home medications
 — A GP practice provided a copy of their amended 
patient leaflet, written to address the problem of 
parental administration, in light of the findings 
of the report
 — One local authority submitted evidence of its 
policy prioritising buprenorphine prescribing for 
parents in treatment 
 — CRI provided details of their home visiting 
procedure
place. The frequency and similarity of the cases 
suggested that the opportunity for national learning 
was not being seized, and that the issue lacked 
national oversight and a coordinated response. 
To form a picture of local responses to these cases, 
requests were made to all local authorities where 
a SCR had taken place, via the LSCB or local drug 
treatment provider, to provide information on their 
current policies and practice and to detail what, 
if any, changes had been implemented either 
as a direct result of the incident or after having 
read Adfam’s report. Of the 17 local authorities 
contacted, four responded with evidence and 
overviews of their policies and procedures. Further 
evidence of local practice was obtained from 
two drug treatment providers that approached 
Adfam to seek guidance on their materials around 
safeguarding children from OST, and from several 
other local authorities and treatment providers 
with which contact had already been established in 
connection with the project. The evidence submitted 
included:
 — The four SCR areas that responded to the 
request for information provided a variety of 
examples of current practice:
 » SCR Area 1 provided an overview of local 
policy and practice and a copy of their patient 
safety agreement
 » SCR Area 2 provided an overview of local 
policy and practice
 » SCR Area 3 provided an overview of local 
policy and practice, a copy of the action plan 
implemented locally in response to a SCR, 
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provided alongside the safe storage box included 
information on the dangers of OST medications 
to children and opioid naïve individuals, the 
importance of safe storage and disposal, legal 
consequences of not storing medication safely 
and warnings against diversion. Using the leaflet 
introduced in Bristol following their ‘Child K’ SCR 
as a template, one local service also developed a 
leaflet containing a list of clear ‘do’s and don’ts,’ 
including an explicit warning not to administer 
methadone to babies and children. 
Safe storage is essential where children and opioid 
naïve individuals are present within the home, and it 
is positive to see that many local areas provide these 
boxes to clients living with children. Other people 
who may be visiting the family home, or with whom 
the child has any contact, should also be provided 
with a safe place to store their medication. Boxes 
must not only be provided, but the safety message 
reinforced by a conversation about the importance 
of safe storage and explicit discussions about 
the risks to children. All professionals who have 
access to the home have a shared responsibility for 
checking on storage arrangements and revisiting 
discussions around safety and risks to children.
2. Intentional administration
The possibility of parental administration of OST 
medications to their children, as identified in the 
original report’s review of SCRs, can be difficult 
for practitioners to accept. We do not know the 
true prevalence of this dangerous practice, and 
 — Preliminary findings on research into the 
prevalence of parental administration of 
drugs to their children was discussed with a 
practitioner in England, as well as evidence of 
local policy.
The evidence submitted suggests that many of the 
measures being adopted locally are in line with the 
recommendations of the original report. The key 
findings are discussed below.
1. Safe storage
The provision of safe storage boxes to service 
users in receipt of take-home medication can be 
an effective tool to reduce the risk of accidental 
ingestions in children and, encouragingly, seems to 
be a widespread practice.12 Information submitted 
highlighted local policies relating to the safe storage 
of medications in the home. All areas reported either 
providing a lockable box13 to clients or assisting in 
purchasing one if the client did not have access to a 
safe storage place for their medication. 
The provision of lockable boxes was said to be 
reinforced by a conversation about the importance 
of safe storage, either at initial assessment stage or 
once the service user was moved from a supervised 
consumption regime and allowed take-home 
medications. One service provided clients with 
digital safe storage boxes (accessible with a code, 
rather than a key) and awarded service users a 
Bronze, Silver or Gold rating, to reflect the safety of 
home storage arrangements. The patient leaflets 
12  This assumption is based on discussions with practitioners across the course of this research and evidence submitted from local areas.
13  The terms ‘safe storage box’ and ‘lockable box’ will be used interchangeably.
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‘If you are taking methadone, you must never give 
any to your child,’ and, ‘Never give your baby or child 
even a tiny amount of methadone or other drug to 
soothe them or help them to sleep.’ 
It was suggested by practitioners in the original 
research that drugs workers may be reluctant to 
accept their clients would engage in such practices, 
and might be overly-cautious in raising the topic 
of intentional administration with clients, out of 
fear of sounding accusatory and damaging the 
worker-patient relationship. Acknowledging this, 
one treatment provider compiled a briefing on 
Medications in Drug Treatment for use on their 
training courses and dissemination to local partners, 
which stated: 
‘Staff may find the concept and discussion of 
intentional administration particularly challenging. 
However, it is a real risk and should be tackled 
directly, including making parents aware that this 
practice is never safe and can be lethal.’
Whilst unequivocal guidance such as this is crucial, 
practitioners nonetheless need to be equipped with 
the skills, competencies and confidence required to 
address challenging issues directly and openly with 
their clients, and supported to employ them.
3. Dispensing regimes
UK guidelines recommend that OST medications 
should be administered daily and under supervision 
for a minimum of three months, with supervision 
relaxed only once the patient’s compliance with the 
it is evident that, in order to address it, different 
methods to those intended to prevent accidental 
ingestions should be employed. For example, 
messages around safe storage are futile if the parent 
is deliberately administering OST medications to 
pacify or soothe the child. There is an identified 
gap in knowledge in relation to the prevalence of 
parental administration, the motivations behind it 
and what can be done to address it. 
The original report additionally found that 
discussions about the toxicity of methadone 
to children and its use as a pacifier were rarely 
considered at assessment or as part of keyworker 
interventions. The evidence submitted of local 
practice revealed little to suggest that this has 
been consistently addressed, or that intentional 
administration is now explicitly and routinely 
discussed with parents in treatment. Whilst leaflets 
and safety agreements contained variations of 
warnings such as, ‘Methadone is very dangerous 
when swallowed by children. Children have no 
tolerance towards the drug and even a tiny amount 
can kill’; only two services appeared to have tackled 
the issue directly and explicitly. Having been 
prompted to review their safeguarding policies 
and practice around this issue by Bristol’s ‘Child K’ 
SCR (where the child was suspected to have been 
administered methadone over a period of time), one 
service’s patient leaflet stated:
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Evidence collected from other local areas confirmed 
that decisions around dispensing regimes take 
into consideration whether children are present 
in the home, and reflect the history, needs and 
risks of the client. However, one service’s action 
plan identified concerns regarding its assessment 
of parenting capacity, and the basis upon which 
prescribing decisions were made. It recommended 
further research into the benefits of supervised 
consumption for parents in treatment, together with 
a deeper consideration of the roles of pharmacists 
and prescribers. The outcomes of this were not 
provided.
4 . Prescribing decisions: methadone v 
buprenorphine
Methadone was the implicated drug in all but one 
of the 20 SCRs examined in the original report, 
and accounted for 15 fatalities. By comparison, 
buprenorphine was implicated in one case, 
which involved the fatality of a 17-year old.17 The 
pharmacology of the two drugs may partially explain 
this stark contrast: buprenorphine carries less risk 
of overdose than methadone, due to its ‘ceiling 
effect’ on respiratory depression, and has been 
described as a ‘valuable therapeutic safeguard.’18  
In addition, whereas methadone is dispensed as 
a green oral liquid formulation, buprenorphine is 
a tablet that must be placed under the tongue for 
three to five minutes, until dissolved. Given the 
pharmacological difference and the unlikelihood of 
regime is assured.14 The relaxation of supervision 
should be a ‘stepped’ process, in which the patient 
continues on daily dispensing, but is no longer 
observed by a professional. As the patient makes 
progress in their treatment, the frequency of 
dispensing can be gradually reduced, and larger 
doses of OST medications allowed to be taken home. 
Research suggests that service users generally 
accept the justification for supervised consumption, 
and agree that all service users should be initially 
supervised.15 The introduction of supervised 
consumption has, in fact, reduced the rate of adult 
methadone-related deaths in relation to the number 
of patients in treatment.16 The risks and benefits 
of take-home OST prescriptions, as opposed to 
supervised consumption, have therefore inevitably 
come under scrutiny when considering how risks to 
children can be minimised. 
In order to provide a more controlled treatment 
pathway, one service adopted a policy whereby 
patients must wait a further 12 weeks after the 
initial three-month supervised period before weekly 
dispensing is considered. Prior to this, clients were 
able to receive weekly prescriptions without delay 
upon reaching the end of the mandatory three-
month supervision. Whilst the service reported some 
initial resistance from clients, it gradually became 
accepted as the norm. In addition, organisational 
policy stipulated that if a risk of diversion was 
identified, the client would be returned to a 
supervised consumption regime. 
14  National Institute for Health and Care Excellence (2007) Methadone and buprenorphine for the management of opioid dependence
15  National Treatment Agency for Substance Misuse (2007) Supervised Methadone in Staffordshire and Shropshire: A study of factors associated with key outcome variables
16  Ibid; Marteau, McDonald and Patel (2015) ‘The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales,’ BMJ Open (Web resource)
17  Whilst the girl who was the subject of the review was said to have expressed suicidal thoughts, the SCR did not conclude whether she had deliberately taken the drug to this end.
18  Schifano et. al. (2005) ‘Buprenorphine mortality, seizures and prescription data in the UK, 1980-2002,’ 20 Hum Psychopharmacol Clin Exp 343
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change from service users but, rather, had found it 
more challenging to encourage GPs to accept the 
potential benefits of prescribing buprenorphine to 
some clients. Their reservations, it was reported, 
were based on a perceived lack of evidence of 
the benefits of buprenorphine, and they cited the 
official guidance, which indicates methadone as the 
preferred option where both appear equally suitable, 
in objection. Cost is another reason often cited in 
support of prescribing methadone, which is less 
costly than buprenorphine.21
Adfam was made aware of another local authority 
(which experienced a SCR) instituting a similar policy. 
The policy, which has been in place for just over a 
year,22 stipulates that buprenorphine should be the 
first option offered to clients entering treatment 
if they have a child of any age. In the event that 
the parent requests methadone instead, a drug 
practitioner must have a discussion of the relative 
risks of buprenorphine and methadone with the client. 
The area also reported good joint-working between 
drug services, social services and health visitors; 
who are all encouraged to discuss safe storage with 
clients. An additional agreement with a local hospital 
was set up, whereby the drug service is notified when 
any adult or child presents at hospital in the accident 
and emergency department having ingested OST 
medications, including the personal details of the 
patient, name of the drug and the name and details 
of the person to whom the drug was prescribed. This, 
it was stated, enables the drug service to review the 
client’s prescription as appropriate. 
a small child placing and retaining a tablet under 
the tongue for more than three minutes, it has been 
proposed (both in studies and anecdotally) that 
buprenorphine presents less risk to children than 
methadone.19
NICE states that the decision about which drug to 
prescribe should be taken on a case-by-case basis, 
and where no drug appears more suitable than the 
other, methadone is stipulated as the preferred 
option, because it is cheaper. However, NICE also 
notes that there is a high mortality risk associated 
with methadone in opioid naïve people, and that the 
clinician should ‘estimate the benefits of prescribing 
methadone or buprenorphine, taking account of the 
person’s lifestyle and family situation (for example, 
whether they are considered chaotic and might put 
children and other opioid-naïve individuals at risk).’20
 
Very few SCRs have recommended a review of the 
respective advantages and risks of prescribing 
buprenorphine over methadone for parents with 
young children. In line with clinical guidelines, 
guidance from one local area reiterated that if a risk 
is identified, buprenorphine should be the preferred 
option. However, a SCR area that submitted their 
action plan, developed in response to their own 
case, has commenced the process of placing all 
parents with children under five on buprenorphine 
rather than methadone. This is in the early stages 
of implementation, and will be a gradual process. 
A practitioner involved in this initiative stated that 
the service had experienced little resistance to the 
19  The research and a deeper discussion of the relative risks of methadone and buprenorphine are laid out in Section Two.
20  National Institute for Health and Care Excellence (2007) Methadone and buprenorphine for the management of opioid dependence
21  This is according to anecdotal evidence and discussions with a range of practitioners across the course of this research.
22  At September 2015
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to addressing their drug dependency showed 
little resistance to buprenorphine as the choice 
medication. Men were said to be typically more 
resistant; the majority of whom did not have children 
living with them, and some were suspected or known 
to want to continue to use illegal substances in 
addition to their prescription. It was this cohort, it was 
reported, that were more resistant to buprenorphine. 
Indeed, service user evidence indicates that 
buprenorphine and buprenorphine-naloxone may be 
associated with reduced rates of continued heroin 
use ‘on top.’25 Drug services, prescribers and the 
LSCB were described as supportive of the policy, 
which has become embedded into local practice.26 
An audit of the policy is planned for the near future, 
and will consider questions such as whether storage 
arrangements are being routinely checked, and 
discussions of safe storage regularly revisited. An 
audit of the agreement with the hospital is also 
planned.
It is worth noting here the new legislation related to 
the distribution of naloxone, which came into force 
on 1 October 2015. The law enables naloxone to 
be supplied to individuals by drug services without 
prescription, including those who use or have used 
opioids and are at potential risk of overdose, and 
carers, family members or friends liable to be on 
hand in case of overdose.27 Naloxone is a medication 
which reverses opioid overdose if given promptly. 
These new rules mean that the drug will now be 
much more widely available across the country. The 
The arrangement was said to be common knowledge 
amongst the treatment population in the area, 
which, as a result, has come to learn of the severe 
consequences of OST medication ingestion. A local 
practitioner said, ‘Parents know the consequences 
of methadone ingestion are worse than those of 
buprenorphine. News travels around the treatment 
community quickly.’ The practitioner went on to say 
that this might be partly contributing to the lack 
of resistance from parents to the prioritisation of 
buprenorphine prescribing over methadone. 
The rationale behind the policy was based on a 
belief that ‘methadone can cause lethargic effects, 
whereas buprenorphine allows parents to operate 
more ‘normally.’’ Anecdotal local evidence was said 
to show that people ‘tend to do better in the long 
term on buprenorphine, which allows for a more 
planned treatment pathway.’ According to local 
practitioners, monitoring data of child protection 
conferences and contact with social care suggested 
that children whose parents are prescribed 
buprenorphine tend to stay on child protection plans 
for shorter lengths of time, and were less likely to 
enter the social care system.23 However, a consultant 
psychiatrist within the service said that people who 
have suffered emotional trauma tend to do better 
on methadone,24 and that this is considered in the 
initial assessment. 
Overall, feedback on the policy was very positive 
and suggested that clients with a commitment 
23  No written evidence of this was submitted.
24  No supporting evidence was provided.
25  Dale-Perera et. al. (2012) ‘Quality of care provided to patients receiving Opioid Maintenance Treatment in Europe: Results from the EQUATOR analysis’, 14(4) Heroin Addiction and Related 
Clinical Problems 23
26  Note that the area does not have GP prescribing: drug treatment providers carry out all prescribing.
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motivated to address their drug dependency.
Enquiries about other adults prescribed OST 
medications who may come into contact with 
children are similarly crucial. Several SCRs 
analysed as part of the original research identified a 
deficiency in this respect: drugs workers sometimes 
tended to focus solely on their client, and 
overlooked the possible risks presented by partners 
and extended family members, or visitors to the 
home. 
Home visits were promoted by practitioners consulted 
as part of the original research, because they provide 
an opportunity to assess home life and identify 
risks, check on storage arrangements, see the child, 
witness parent-child interactions and fully explore 
the needs of the family. Many services operate 
home visit procedures, although their exact nature 
will differ. One service (which had been prompted 
by Adfam’s report to reconsider their own practice) 
was of the belief that in order to make an effective 
whole-family assessment, a home visit must be 
conducted, including the homes of all clients where 
children regularly visit: for example, the homes of 
grandparents.  A policy implemented by another 
treatment provider demanded that mandatory 
home visits for all patients entering treatment with 
children under five be conducted. Another opted for 
a joint home visiting protocol with the local children, 
family and adults service; which insisted that 
storage arrangements be checked, and facilitated 
information-sharing and recording processes. 
CRI, a national treatment provider, also provided 
guidance released, however, does not touch upon 
the use of naloxone to counteract the effects of child 
ingestions of opioids.28
5. A whole-family approach to assessment
The evidence and materials submitted demonstrated 
a clear recognition of the importance of a 
comprehensive, whole-family approach to 
assessment. Guidance issued by one service 
strongly emphasised the need for whole-family 
risk assessments, and encouraged the inclusion 
of family members in assessment, including an 
exploration of the child’s point of view. Discussions 
with practitioners and services over the course of 
this research suggest that it is common practice 
for services to enquire about children living or 
in contact with the service user at assessment. 
One local area reported that a Child and Family 
Assessment had only been introduced following a 
local SCR where a young child died after ingesting 
methadone. Another service developed an audit 
questionnaire to help professionals conduct 
effective risk assessments; prompting them to 
consider whether there are any cohabitants, 
whether there is a process in place to observe the 
prescribing regimes of both parents (if both are 
in treatment), a historical review of the client’s 
treatment journey and processes for challenging 
information and best practice on working with 
uncooperative families. The same service also 
promotes the use of pre-birth assessments, having 
acknowledged that pregnancy provides a valuable 
opportunity to engage parents, and particularly 
mothers, at a time when they are often highly 
27  The Human Medicines (Amendment) (No. 3) Regulations 2015
28  Public Health England (2015) ‘Take-home naloxone from October 2015’ (Web resource)
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Board’s Professional Capabilities Framework to, 
amongst other things, inform social work training 
and continuing professional development. Several 
respondent local areas indicated they believed there 
was a need for training to improve professional 
competency and build on the skills of the 
workforce. One service, in a local authority which 
had experienced a SCR involving a non-fatal child 
ingestion of methadone, successfully incorporated 
OST-specific issues into the multi-agency Hidden 
Harm training it is contracted to deliver locally. 
Another provider, in accordance with the local 
action plan developed in the wake of a SCR, has 
since then delivered multi-agency training covering 
safeguarding children from OST to over 400 health 
visitors, in addition to a range of other professionals 
in the drug, children’s social care and health sectors. 
One local service, prompted to review their policies 
and practice by Adfam’s report, likewise recognised 
the need for clarity amongst all professionals 
involved, and support for them to develop their skills 
and feel confident in implementing professional 
challenge and curiosity. The service is currently 
assessing how it could incorporate OST-specific 
content into the compulsory training already 
provided by the LSCB, in addition to how best to 
train and educate the workforce on recognising 
the signs of disguised compliance.30 Guidance 
issued to services in another local area urged 
against professional over-optimism, and another 
encouraged ‘healthy scepticism’ and ‘respectful 
uncertainty’ in their staff. It is possible to infer from 
the evidence submitted that services recognise 
evidence of their safeguarding children policy, which 
stipulates that a home visit must be conducted 
within five working days of the parent entering 
treatment, if they have a child living with them. The 
purpose of home visits was said to be manifold: to 
check on safe storage, ascertain if there are unmet 
needs in the home and to observe the child with the 
parent. Home visits were additionally said to help 
build a bigger picture of the client’s environment, 
to inform the recovery plan and direct the client 
towards appropriate services (such as children’s 
centres), if necessary. If it is not possible to conduct 
a home visit within five working days, drugs 
workers must provide the client with a lockable box; 
explaining the purpose of the box, discussing the 
risks to children and arranging a time for a home 
visit to be conducted. The policy expects staff to 
be explicit in their discussions with clients, and 
encourages joint home visits with health visitors or 
social workers, where appropriate. This policy was 
recognised not as a ‘catch-all’, but was said to be 
effective in highlighting the seriousness of the issue 
to both drug treatment staff and parents. 
6. Professional competency, curiosity and 
challenge
The Munro Review of Child Protection29 highlighted 
how the problem of prescriptive practice - a 
‘tick-box culture’ - had restricted professionals’ 
ability to exercise professional judgement. It 
therefore encouraged workforce development, 
the development of professional learning, and 
advocated for the use of the Social Work Reform 
29  Munro (2011) The Munro Review of Child Protection: Final Report
30  ‘Disguised compliance’ involves a parent or carer giving the appearance of co-operating with services to avoid raising suspicions, to allay professional concerns and ultimately to diffuse 
professional intervention. The term is attributed to Reder, Duncan and Gray, who outlined this type of behaviour in their book ‘Beyond blame: child abuse tragedies revisited.’ (Reder et. al. 
(1993) Beyond blame: Child abuse tragedies revisited. London: Routledge)
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Following a fatal child ingestion of methadone, 
one drug treatment service implemented a 
recommendation that was made in the SCR overview 
report into the child’s death, and developed a 
‘pathway…to ensure multi-agency assessment is 
always undertaken.’ To this end, training sessions 
were delivered to health visiting teams across 
the county, complimented by the introduction 
of practice guidance and an assessment tool for 
health visitors working with parental substance use 
(focusing on parents in the methadone programme). 
The treatment service also transferred their 
data information system to that used by GPs and 
health professionals locally, in order to facilitate 
information-sharing. The practice guidance issued 
to health visitors recommended minimum monthly 
contact if a child is on a safeguarding plan, and 
home visits every three months for children under 
two, not on a safeguarding plan. It also encouraged 
the development and use of professional judgement, 
as well as adherence to the assessment tool 
containing an extensive list of prompts. Risk 
assessments carried out by the drug service are sent 
to health visiting teams via the secure email system 
and reviewed every three months, and clients are 
informed on entering treatment with whom and 
under what circumstances personal information will 
be shared. 
An audit of referrals from the drug service to health 
visitors was conducted, which analysed a random 
selection of electronic records. A total of 46 referrals 
were made in the six-month period reviewed, with 
24 cases included in the audit. Results showed 
that 23 of the 24 records were clearly documented, 
the importance of such skills in minimising risks 
to children, and isolated efforts are being made to 
build workforce competency. However, more needs 
to be done to ensure that training to instil such skills 
within the workforce, including drug treatment, 
health and social care providers, is delivered across 
the country.
7. Joint-working and information-sharing
Multi-agency collaboration was another process 
that was considered key to an effective and robust 
local safeguarding policy, and many local areas 
highlighted their links with partner agencies. Several 
services described their processes of joint-working 
between children’s social services and drug treatment 
providers. One local treatment provider said they 
contacted social services if there had been prior 
involvement between the child and social care, and 
liaised with them regardless of previous contact 
where there were concerns. Another service reported 
having implemented joint early help assessments 
with social services for service users and families, 
and a further two local areas were said to convene 
multi-agency meetings with drug treatment workers 
and managers, health visitors and social workers 
in attendance. It must be remembered, however, 
that joint-working - necessary to an effective 
holistic approach to care - means more than just 
communication between the drug provider and social 
services; it requires the collaboration of a much wider 
range of practitioners, including health visitors, 
prescribers, GPs, community pharmacists, midwives, 
school nurses, the police, LSCB and any other 
services working with the family. 
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submitted by a treatment provider also proposed 
the introduction of a joint protocol for information-
sharing and reporting. It is not known, however, 
whether this has been successfully introduced, 
since no progress information on implementing the 
plan was provided.
8. Other measures
Through continued discussions with practitioners 
and agencies over the course of this project, it 
seems that many local areas have taken comparable 
actions to address this particular risk to children. 
Examples of practice, whilst not commonplace, 
included:
 — Specialist workers: A drug treatment service 
in England reported having appointed 
two specialist family workers: one to work 
with pregnant service users and another 
with families. The value of such roles was 
recognised in the 2015 (‘Child BT’) Blackpool 
SCR (discussed below), where the panel, as 
well as detailing missed opportunities, also 
considered examples of effective practice for 
wider learning. The drug service from which 
the mother in the case was receiving treatment 
operated a clinic for pregnant women who 
were using opioids, and employed a specialist 
midwife. This model was highly commended by 
the review panel, which emphasised the need 
for strong links amongst agencies in order for 
safeguarding concerns to be shared and acted 
upon quickly and effectively. Specialist workers, 
dedicated to family work, were also considered 
to help a service maintain a whole-family focus.
21 showed evidence that the guidance for home 
visiting had been followed, 22 recorded safe 
storage arrangements having been checked and 
20 records provided evidence of additional sharing 
of information with the drug service, GP, multi-
agency team and other agencies. Of the records 
reviewed, there was evidence of only one joint 
home visit carried out between the health visitor 
and drugs worker. A joint home visit, according to 
local guidance, should be conducted if (i) there is 
a history of disengagement with health visiting, 
midwifery or drug treatment services, (ii) there is 
involvement with social care or an identified risk, 
(iii) there is significant use of alcohol alongside 
drug use or prescribed medication, (iv) active drug 
dealing is identified or suspected, or (v) there is 
a history of domestic abuse. In all other cases, 
guidance states that professionals are expected to 
use their professional judgement, ‘based on case 
history and current involvement.’ The process is still 
very new and will need time to embed, but these 
results are nonetheless a promising example of 
effective joint-working between drug treatment and 
health visiting teams to better safeguard children. 
Further examples of embedding joint-working 
into local practice included materials produced 
to emphasise the role of all professionals in 
safeguarding children against the risks of OST - 
especially those visiting the home - and guidance 
for professionals around providing and reinforcing 
safety advice, regularly reviewing safety plans, 
sharing information and monitoring children 
for signs of intoxication. One local action plan 
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a costly policy, which may give rise to issues 
around consent. The reliability of such tests 
has also been called into question in court.33                    
It is therefore an area worthy of clarification, 
and requiring local agreement. 
 —
 — Another area from which evidence was gathered 
reported that it was seeking to secure funding 
for an initiative to hair strand test all looked              
after children.34  
Conclusion
Safeguarding children from the risk of OST ingestion 
requires a coordinated effort, and it should be 
recognised that any of the above measures in 
isolation are unlikely to eradicate risk. The evidence 
gathered shows that some local authorities have 
recognised the need to strengthen and improve 
their ways of working in order to better safeguard 
children, and have taken proactive steps to address 
this issue. Whilst the evidence provides a mere 
snapshot of current practice, it does indicate that 
many local services are taking similar steps, for 
example: providing safe storage boxes and advice, 
working to improve professional knowledge and 
competencies, and developing joint-working 
protocols. 
All respondent areas stated that they routinely 
provide parents in treatment with a safe place 
to store their medication (apart from one which 
assists in purchasing a lockable box if the client 
 — Specialist programmes: One LSCB devised, 
with partners, a multi-agency strategy and 
action plan, which was promoted by the local 
Health and Wellbeing Board as well as the 
LSCB, and has prompted a review of the range 
of services available locally to parents receiving 
drug treatment services. Having identified a 
gap in local provision, a parenting programme 
was developed, which now forms part of the 
core offer to parents in treatment with children 
under five. The programme runs over 10 weeks 
and aims to support and educate parents, 
whilst promoting self-esteem and motivation 
for a healthy lifestyle and positive parenting. 
An evaluation of the pilot of the programme 
showed a number of positive outcomes for 
the participants, including increased mental 
wellbeing,31 greater engagement with available 
services and better family relationships. 
Following a successful pilot, further funding 
has been awarded to continue to provide the 
programme.
 — Hair strand testing for children: The same 
local authority also implemented a policy of 
hair strand testing all children under five where 
social care are actively involved, and where child 
ingestion is suspected. More information was 
requested, but none was provided. Whilst one 
study32 suggested that hair strand testing was 
a useful way of detecting drug use in children’s 
environments, it is worth noting that this is 
31  This was measured using the Warwick Edinburgh Mental Wellbeing Scale, which learners completed at the beginning and end of the course.
32  Pragst et.al. (2013) ‘Methadone and illegal drugs in hair from children with parents in maintenance treatment or suspected drug abuse in a German community,’ 35(6) Ther Drug Monit. 
737. Discussed in Section Two
33  Bristol City Council v A and A, and SB and CB, and Concateno and Trimega [2012] EWHC 2548 (Fam)
34  This had not been approved by September 2015.
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children. Some practitioners felt that such candid 
conversations would be challenging to undertake 
without sounding accusatory, and to do so would 
therefore risk the service user’s engagement and 
damage the worker-client relationship. 
The answer to this is effective training to equip 
practitioners with the skills to conduct challenging 
conversations and broach difficult topics directly 
and openly with their clients. As was suggested 
by one practitioner: using a SCR example to 
demonstrate the dangers of OST to children, 
rather than presenting it as an identified risk 
for the individual, could be a useful and non-
threatening way for practitioners to raise the issue 
with their clients. Other methods could include 
enquiring about the child’s sleeping patterns and 
how this affects the parents; indirectly assessing 
whether the parents are struggling to cope with 
an unsettled child, and the risk of OST drugs being 
used as a means of pacification. Practitioners must 
acknowledge that poor parenting practices can 
sometimes take place in their client group, be fully 
aware of the risks of OST to children, and should be 
supported to be able to approach the subject in a 
non-punitive manner, keeping both the parent’s and 
child’s interests in mind. The importance of health 
visitors is relevant here: being concerned primarily 
with the health and wellbeing of young children, 
and trained to recognise vulnerable families, having 
knowledge and understanding of the risks of OST 
to children should be integral to the health visitor’s 
assessment.
did not have a secure storage place). Whilst this is 
a simple and thus attractive solution, it should be 
stressed that it is not a solution in itself. The risk 
of complacency once a safe storage box is issued 
was identified in the original report: practitioners 
sometimes assume their responsibility for managing 
risk is satisfied by the mere provision of a lockable 
box. Discussions of safe storage boxes are also 
defunct when faced with the problem of intentional 
parental administration. Nonetheless, clients in 
treatment who have contact with children must 
be provided with a secure place to store their 
medication if they are prescribed take-home doses, 
and this should be reinforced by a conversation 
with a professional about the importance of safe 
storage and the risks to children associated with 
OST ingestion.
In order to reduce the risk of parental 
administration, leaflets and safety agreements 
must carry explicit and direct warnings of the 
risks of OST drugs to children, which should be 
accompanied by an open conversation with the 
client. Practitioners interviewed for the original 
report proposed a number of reasons why the issue 
of intentional administration may not be routinely 
discussed with patients. It was suggested that staff 
were less familiar with the practice of intentional 
administration than with the risks associated 
with OST more generally, and that practitioners 
may not think to initiate a conversation about the 
risks, based on a presumption that the parent 
would already be aware of the risks of OST to 
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an accurate picture of the entire family around the 
child, and in making effective risk assessments to 
inform the client’s recovery plan, according to the 
evidence submitted. 
The audit of health visitor referrals provided by one 
area is a promising model, and gives support to the 
development of inter-agency joint protocols. In order 
for practitioners to have a ‘whole picture’ of the 
family, inter-agency cooperation and communication 
is crucial. In line with Working Together35 and NTA 
guidance,36 local authorities should consider the 
creation of inter-agency joint protocols to facilitate 
information-sharing, and better manage risk. The 
Child Protection-Information-Sharing (CP-IS) project, 
an NHS England initiative, could also be a useful tool 
to facilitate information-sharing, and conducive to 
early intervention. The project, if buy-in from local 
authorities is achieved, will link the IT systems of NHS 
unscheduled care to those used by social care child 
protection teams, so that information can be shared 
about three specific categories of child: those with a 
child protection plan, those classed as looked after 
and any pregnant woman whose unborn child has 
a pre-birth protection plan. Children entering A&E, 
outpatient departments, other unscheduled care 
settings and unborn children subject to a pre-birth 
protection plan will be flagged up as vulnerable. 
However, this measure is limited, given that it only 
applies in NHS settings, and would be of more benefit 
if it were to be extended or replicated to all providers 
of children’s services (for example, health visitors).
We do not know how commonplace the practice 
of intentional administration of OST drugs to 
children is amongst the treatment population. 
Whilst anecdotal evidence and the review of SCRs 
between 2003 and 2013 would suggest that it 
certainly occurs, research to estimate the scale of 
the problem is lacking. The 20 SCRs examined in 
the original report included five confirmed cases of 
intentional administration by the parents, and in a 
further six cases, it was unclear how the child came 
to ingest the drug. Further research into how and 
why parents may administer drugs to their children 
is advised, to ascertain its prevalence amongst the 
treatment population, to raise awareness of the 
practice amongst professionals and to effectively 
tackle it in practice.
The need for a ‘whole-family approach’ was 
recognised by several respondent services. A 
robust assessment of risk to the child demands that 
the whole family and environment is considered. 
Specialist family workers in drug treatment services 
could help ensure and maintain a family focus, 
and multi-agency training should seek to embed 
a family mentality within the workforce, as well as 
instilling wider knowledge and skills. As previously 
highlighted; male service users, in particular, must 
be frequently asked about contact with children, 
since they are more likely to be transient and their 
relationship status can quickly change. Female 
service users should be frequently asked about new 
partners and people visiting the family home. Home 
visits were considered an invaluable tool in forming 
35  Department for Children, Schools and Families (2010) Working together to Safeguard Children: A guide to inter-agency working to safeguard and promote the welfare of children
36  National Treatment Agency for Substance Misuse (2010) Supporting Information for the Development of Joint Protocols between Drug and Alcohol Partnerships, Children and Family Services
25 Medications in Drug Treatment: Tackling the risks to children - one year on
prescribers should exercise professional judgement, 
in collaboration with others, and base decisions 
firmly on robust risk assessments, with particular 
consideration of risks to children. Whilst it may at 
first seem like a simple ‘catch all’ solution to place 
parents and those in contact with children on a 
supervised consumption regime indefinitely, it 
must be remembered that treatment services offer 
a protective factor for the child, and excessively 
rigid dispensing policies may risk the parent’s 
engagement with treatment. Clients with children 
will necessarily find it more difficult to attend a 
pharmacy daily, due to childcare responsibilities, 
and there is evidence to suggest that client 
satisfaction is higher the less frequently they are 
required to collect their medication.37 Rather than 
a blanket rule such as this, a more proportional 
response would be to base decisions on the 
frequency of dispensing on robust and informed risk 
assessments, following input from all professionals 
involved with the family. 
Some local areas have also initiated a move towards 
the preferred prescribing of buprenorphine for 
parents in treatment, based on the belief that it 
poses less risk to children. Early anecdotal evidence 
suggests that these policies have elicited only 
initial resistance from some clients, whilst many 
have accepted the rationale without challenge. 
Section Two contains a deeper discussion of these 
prescribing decisions.
Of particular importance when considering 
professional competencies are the concepts of 
professional challenge and curiosity, bearing in 
mind the professional tendency towards over-
optimism identified in SCRs and research for 
the original report. Findings from several SCRs 
suggested that professionals working with the 
families had been overly optimistic; accepting 
their clients’ explanations without challenge 
and, as a result, missing signs that would have 
indicated that the child in question was at risk. 
Professional curiosity and challenge is crucial 
for workers in tackling disguised compliance and 
intentional administration - both in recognising 
the signs of ingestion in children, and being open 
to the possibility that their clients might engage 
in the practice. Training to instil these skills within 
the workforce is critical, together with ongoing 
support (such as regular supervision) for frontline 
practitioners to be able to confidently put these 
skills into practice.
A lack of uniformity in both dispensing regimes and 
prescribing decisions was evident when reviewing 
the information submitted by respondent services. 
When supervised consumption is reduced or 
stopped, it is essential that a robust risk assessment 
is carried out to assess the suitability of take-home 
medication, with particular consideration of risks 
to children. Rather than automatically allowing 
weekly prescriptions when the three-month 
supervision period comes to an end, services and 
37  Amass et.al. (1998) ‘Alternate-day buprenorphine dosing is preferred to daily dosing by opiate-dependent humans. Psychopharmacology,’136(3) PubMed 217
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This section has provided examples of actions 
taken by local authorities and individual services 
to minimise the risks to children posed by 
OST medications in the home. It would be an 
exaggeration to suggest that the amount of 
evidence gathered allows for the formation of an 
accurate picture of local policy and practice across 
the country, and further information on the progress 
of the actions detailed above was not provided in 
many cases. The ad hoc nature of the actions taken 
in different local areas emphasises the need for a 
nationally-driven, coordinated response to prevent 
more child deaths. Nonetheless, it is encouraging to 
see that isolated actions are being taken to better 
safeguard children from the risks posed by these 
drugs, and it is hoped that the examples of local 
practice provided above will encourage further 
progress towards this aim.
Section two: 
Estimating the scale of 
the problem
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Section two: Estimating the scale of the problem
38  Advisory Council on the Misuse of Drugs (2003) Hidden Harm
39  Manning et. al. (2009) ‘New estimates on the number of children living with substance misusing parents: results from UK national household surveys,’ 9 BMC Public Health 377
40  HC Deb 29 October 2013, vol 569, cols 439-440
Medications in Drug Treatment set out to gather all 
SCRs where OST medications were implicated in 
harm to a child between 2003 and 2013. It found that 
20 SCRs, involving 23 children, had been conducted 
during this period (17 in the latter five years). These 
included 17 fatalities and six non-fatal ingestions 
– not forgetting the additional number of ‘near 
misses’ and incidents that did not result in a SCR. 
Methadone was mentioned in 19 of the 20 SCRs, 
and was responsible for 15 fatalities. Buprenorphine 
was responsible for one. The literature review 
similarly yielded little information from which an 
accurate estimate of the number of children at risk, 
or the number of child ingestions, could be reached. 
However, since the publication of the report last year, 
some of the figures contained therein have been 
updated, and new evidence obtained. This section 
provides available updates to the statistics contained 
in the report, as well as presenting new information. 
1. The number of children affected by 
parental drug use
The 2003 estimate that there are 250,000-350,000 
children of problem drug users in the UK38 has long 
been considered an underestimation, largely based 
on the fact that it is an extrapolation of treatment 
data alone. A 2009 study39 sought to obtain a more 
accurate picture of the number of children living in 
the UK affected by parental substance use, and found 
that around one million children lived with an adult 
who had used an illicit drug in the past year, and just 
under half a million with someone who had done so 
in the past month. It also revealed that the number of 
children living in a household where the only adult was 
a drug user had more than doubled between 2000 and 
2004/5, and that 334,000 children were estimated to 
be living with a dependent drug user. However, this 
data is similarly limited, given that it is based upon 
self-reported evidence by the parents. The real number 
of children affected by parental drug use can thus be 
assumed to be higher than these figures suggest.
2. The number of people with parental 
responsibility receiving a prescribing 
intervention
Following a Freedom of Information request, a 
breakdown of the number of adults in each English 
local authority receiving a prescribing intervention for 
opioid dependency and with parental responsibility 
in 2012-2013 was obtained; totalling 61,928 across 
England – an increase on the 60,596 recorded in 
2011-12.40 The number of OST patients with parental 
responsibility varied significantly between local 
authorities: ranging from Birmingham with 2,100, 
to Bracknell Forest with 21. When comparing the 
number of SCRs with the high numbers of people 
receiving a prescribing intervention who have parental 
responsibility, it is clear that OST presents a risk factor 
in proportionally very few families. A breakdown of the 
number of parents on supervised consumption regimes 
versus take-home doses is not provided; therefore, 
the number of children living in households where 
OST drugs are stored in the home is still unknown. 
This is important since we know that the majority of 
exposures to OST medications occur within the child’s 
own home.
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3. The number of children admitted to 
hospital due to methadone ingestion
It was recommended in the original report that 
data should be centrally collected on the number 
of under-18s admitted to hospital following 
the ingestion of OST medications. It has since 
been discovered that the Health and Social Care 
Information Centre (HSCIC) collects figures on 
hospital diagnoses of methadone poisoning in 
England, but not of buprenorphine poisoning.41 
Between 2003 and 2013, these figures show that at 
least 310 children (0-17) were admitted to hospital 
and diagnosed with methadone poisoning.  Until 
the 2012-13 report, the age breakdown did not 
allow for distinction between children aged 15 and 
above and adults (the age category being 15-59 
years). Consequently, the number of children aged 
15 and above who were hospitalised after ingesting 
methadone is not included in this statistic. 
The two most recent reports provide a much 
more detailed breakdown of age. In 2012-13, 15 
under-fives were admitted to hospital as a result 
of ingesting methadone: on average, one every 
24 days. A total of 25 children were admitted to 
hospital with methadone poisoning during that year. 
The most recent set of figures available (2013-14) 
show that 18 children presented at hospital with 
methadone poisoning; seven of whom were under 
five.42 These figures, whilst distressing and startling, 
provide a much needed realistic estimation of 
the scale of the problem. They also illustrate the 
41  Health and Social Care Information Centre, Hospital Episode Statistics, Admitted Patient Care – England, 2003-13. (Appendix 1). Coding was changed for the 2012-13 report, and provided 
a narrower breakdown of patient ages.
42  HSCIC (2014) Hospital Episode Statistics, Admitted Patient Care – England, 2013-14
43  Office for National Statistics (2015) Deaths related to drug poisoning in England and Wales, 2014 registrations (Web resource)
44  No further age breakdown was provided
ineffectiveness of SCRs as a means of measuring 
the incidence of OST ingestion in children. However, 
these figures capture only hospital admissions in 
England, do not provide an estimation of the number 
of children admitted to hospital with buprenorphine 
poisoning and, for the majority of the time period, 
children aged 15 and above were not accounted for. 
As a result, the total number of children throughout 
the UK that have been hospitalised due to all OST 
medications since 2003 presumably exceeds the 328 
identified.
4. New drug-related death statistics
The latest data to be released by the Office for 
National Statistics on deaths related to drug 
poisoning in England and Wales was published 
in early September 2015.43 After several years 
of decreasing levels of drug-related deaths, the 
last two years have seen an increase to record 
highs, with a total of 3,346 drug poisoning deaths 
registered in 2014. The number of deaths involving 
methadone, however, was down 8% on the previous 
year: from 429 in 2013, to 394 in 2014; representing 
11.8% of the total number of drug-related deaths. 
Three of the 394 methadone-related deaths involved 
persons aged under 20, yet it is unknown whether 
these three deaths involved under-18s.44
The number of deaths involving buprenorphine is 
not provided in the main publication, although it is 
reasonable to assume these deaths form a portion 
of those in the ‘other specified opiate’ category. 
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However, a complete set of the data is available to 
download separately;45 which shows that in 2014, 
24 deaths were registered where buprenorphine 
was mentioned on the death certificate – an 
increase on the 13 registered in 2013.46 The table 
categorising the number of drug-related deaths 
by age and selected substances mentioned on the 
death certificate does not provide a breakdown of 
those deaths relating specifically to buprenorphine. 
Rather, these deaths are included in the ‘other 
specified opiate’ category; of which, three deaths 
occurred in under-20s. (This was confirmed by an 
ONS researcher, with whom contact was made in 
order to request data on the number of under-
18s that had died in 2014 where methadone or 
buprenorphine was involved. This data, however, is 
not made readily available, and was not provided).47 
It cannot be ascertained whether these three deaths 
did in fact involve buprenorphine or another opioid, 
nor whether they involved children.48
5. The number of child deaths related to 
ingestion of OST medications
In researching the original report, it became 
apparent that child mortality statistics where OST 
was implicated were not publicly available, and did 
not appear to be centrally held. However, data on the 
number of child deaths in each of the countries of 
the United Kingdom has since been obtained: from 
the Office for National Statistics (ONS), Northern 
Ireland Statistics and Research Agency (NISRA) 
45  ONS (2015) Deaths related to drug poisoning, 2014 - Reference Tables (Excel sheet 469Kb) (Web resource)
46  Ibid, Table 6a
47  Such data is released payable to a fee.
48  Ibid, Table 7
49  The data was released upon payment, and is not accessible otherwise i.e. it is not in the public domain.
50  ONS (2013) Deaths Related to Drug Poisoning in England and Wales 2009 – 2013 (Web resource)
and National Records of Scotland (NRS). These are 
set out below. It must be borne in mind that these 
data are not in the public domain and cannot be 
independently verified.49
i. England and Wales
The mortality statistics released by the ONS include 
all registered deaths in England and Wales related 
to drug poisoning, categorised by age, sex, causality 
and by means of intent or accident.50 Whilst the total 
number of deaths related to methadone poisoning 
across all age categories is recorded, no detailed age 
breakdown is provided, and it cannot be discerned 
how many of these deaths involved children. Given 
this lack of publicly available information, contact 
was made with the ONS to request data for all deaths 
involving persons up to and inclusive of the age of 
18, registered between 2003 and 2013, in England 
and Wales that were related to methadone and 
buprenorphine. The statistics provided are shown in 
Tables 1 and 2 overleaf.
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The table above shows that between 2003 and 2013, 
72 deaths from methadone poisoning were registered 
in England and Wales, for persons up to the age of 18 
inclusive. The ONS initially provided a breakdown of 
deaths in 0-14 and 15-19 age categories. A request 
was subsequently made to further breakdown the 
15-19 age category, to include only those aged 15-18. 
Rather than providing an annual breakdown of deaths 
in the 15-18 year old category, the ONS provided the 
combined figure for the number of 15-18 year olds 
that had died over the 10-year period; showing that 
between 2003 and 2013, 13 under-15s and 59 persons 
aged 15-18 died from methadone poisoning. The ONS 
does not hold information about individual cases and 
was unable to provide details of the circumstances of 
death, including sex, locality, whether the methadone 
was prescribed to a parent or carer or whether the cases 
involved accidental or intentional administration.51
Evidently, there is a striking discord between these 
statistics and the number of SCRs analysed as part 
of the original report. The 15 methadone-related 
fatalities identified in the report show only a fraction 
of the child deaths related to methadone poisoning 
occurring over this time period. Of the 13 fatalities in 
the 0-14 age group, seven did not result in a SCR. It 
was not possible to cross-reference deaths in the 15-18 
age group, given that an annual breakdown was not 
provided. In addition, an age-bias towards younger 
children was identified in the SCRs in the original 
report – the median age of the child being just two 
years old. However, the above dataset suggests that 
these findings were not representative of the typical 
age of children dying from methadone poisoning.
Registration 
year
2003 
2004 
2005 
2006 
2007 
2008 
2009 
2010 
2011 
2012 
2013
Total number of reported meth-
adone-related deaths in the 
0-14 age group (13 deaths)
1 (Camden (Child ‘B’))
0 
1 (North Yorkshire (Child 
‘SNM’))
1 (Plymouth (Child ‘LB’))
0 
2 (Nottingham City (Child 
‘Thomas’), Staffordshire 
(‘Child aged 3’))
0 
0 
1 (Bristol (Child ‘K’))
0 
Identified SCRs in the 
original report
1 (Camden (Child ‘B’))
0 
1 (North Yorkshire (Child ‘SNM’))
1 (Plymouth (Child ‘LB’))
0 
2 (Nottingham City (Child ‘
Thomas’), Staffordshire 
(‘Child aged 3’))
0 
0 
1 (Bristol (Child ‘K’))
0 
0
Total number of methadone-related 
deaths in the 15-19 age group (59 
deaths – 15-18 year olds)*
5 
10 
9 
9 
11 
17 
12 
8 
13 
6 
1
 *A further age breakdown for the entire period was later provided. See below.
Table 1: Total number of deaths by methadone poisoning for those up to the age of 19 
inclusive in England and Wales, registered between 2003 and 2013
51  It should be noted that these figures relate to deaths in England and Wales where methadone was mentioned on the death certificate.
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Table 2 shows that between 2003 and 2013, 19 
people aged 19 or under died from buprenorphine 
poisoning. Unlike the dataset above, the ONS failed 
to provide a further breakdown of the 15-19 year old 
age category for buprenorphine-related deaths. As 
a result, it cannot be determined how many of the 
deaths listed above involved persons aged 15-18. 
However, according to this data, no children aged 
0-14 died from buprenorphine poisoning during 
this period, thus illustrating a strong bias towards 
adolescents in buprenorphine-related deaths. 
The one SCR involving buprenorphine, which was 
analysed as part of the original research, related 
to the death of a 17-year old – ‘Child E’, Cumbria 
(2010). Why this case warranted the undertaking of 
a SCR whilst others did not is unknown. Statutory 
guidance states: ‘when a child dies (including 
death by suicide) and abuse or neglect is known 
or expected to be a factor in the death, the LSCB 
should always conduct a SCR into the involvement 
of organisations and professionals involved in the 
lives of the child and the family.’52 ‘Child E’ was well 
known to local agencies: her child was subject to 
a child protection plan, she herself had previously 
been in the care of two local authorities, served 
a period of detention in a secure children’s home 
and had her name placed on the child protection 
register three times. She had also been admitted to 
a psychiatric ward shortly before her death, and was 
treated for depression.
It may be that the panel did not consider the 
threshold for a SCR to be met in the other cases 
recorded in the table above, because they were 
not suspected to have involved neglect or abuse, 
or because there simply was no professional 
involvement with the child or family. If no 
professionals were involved with the family, a SCR 
would unlikely be conducted. There is also scope 
for differing interpretations of ‘abuse’ and ‘neglect’ 
ONS registration year
2003 
2004 
2005 
2006 
2007 
2008 
2009 
2010 
2011 
2012
2013
Total number of deaths in the 0-14 age group
0
0
0
0
0
0
0
0
0
0
0
Total number of deaths in the 15-19 age group
0 
1 
3 
1 
3 
2 
1 
3 (1 was Cumbria ‘Child E’)
2 
3 
0
Table 2: Total number of deaths by buprenorphine poisoning for those up to the age of 19 
inclusive within England and Wales, registered between 2003 and 2013
52  Department for Children, Schools and Families (2010) Working together to Safeguard Children: A guide to inter-agency working to safeguard and promote the welfare of children
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amongst local authorities, and this may be one 
of the reasons why some child ingestions of OST 
medications resulted in SCRs whilst others did not. 
In areas that receive large amounts of child in need 
referrals, it may be speculated that thresholds are 
likely to be higher. 
ii. Northern Ireland
The NISRA annually publishes statistical data on 
drug-related deaths. In the 2003-2013 report,53 
a total of 24 drug-related deaths across all age 
categories where methadone was mentioned on 
the death certificate were recorded. NISRA was 
contacted and a request was made to provide the 
number of deaths involving those aged 0-18 during 
this period where methadone and buprenorphine 
were mentioned. It advised that none of the 24 
methadone-related deaths that occurred during 
this 10-year period were registered in the 0-18 age 
group. In addition, it claimed that no buprenorphine-
related deaths were registered in the 0-18 age group 
between 2003 and 2013. No statistical data was 
provided by NISRA to verify this, and it was unable 
to comment as to why deaths may not have been 
registered.
iii. Scotland
In Scotland, the NRS produces and archives all 
statistics monitored on an annual basis, and holds 
information on all registered deaths. The NRS was 
contacted, and Adfam was provided with a set of 
data containing all drug-related poisoning deaths 
from 2003 to 2013 for those up to and including 
the age of 18, with corresponding classification 
codes. Deaths are classified under the International 
Statistical Classification of Diseases and Related 
Health Problems (ICD-10), which is a comprehensive 
classification of causes of morbidity and mortality, 
maintained by the World Health Organisation 
(WHO). The information in the table below (Table 
3) has been summarised and condensed to include 
only relevant information for the purposes of this 
report. The ‘Drug(s) Involved’ column lists those 
drugs, which according to the coroner’s report,       
were found in the body at the time of death.
Table 3 (overleaf) shows that between 2003 and 
2013, 37 deaths were registered in Scotland, 
involving persons up to and including the age of 18: 
35 related to methadone, and two to buprenorphine. 
The two buprenorphine-related deaths included that 
of a 14 year old who, according to the information 
provided, died from buprenorphine and diazepam 
intoxication, with undetermined intent (i.e. we do 
not know whether the child used it as a drug of 
abuse or intended to overdose). However, the NRS 
website states that, for the purpose of statistics, 
deaths classified as such can be counted as 
probable suicides.54 The second was that of a 16 
year old, which was deemed to have been a case of 
accidental poisoning. The two deaths of children 
under five involved a new born and two year old; 
the cause of death in the former was noted as, 
‘Combined effects of mechanical Asphyxia55 and 
Methadone (from breastfeeding)’ and in the latter, 
‘Methadone toxicity.’ This latter case was deemed 
53  Northern Ireland Statistics and Research Agency (NISRA), Tables for Drug Related Deaths due to Drug Misuse Registered in Northern Ireland, 2003- 2013 (Table 4)  
54  National Records of Scotland (date unpublished) ‘How NRS Classifies Deaths for Statistical Purposes as (Probable) Suicides’ (Web resource)
55  Mechanical asphyxia is a form of asphyxia caused by a mechanism that prevents lung ventilation i.e. smothering.
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Year
2003
2003
2003
2004
2004
2005
2005
2005
2005
2005
2005
2006
2006
2007
2007
2007
2007
2008
2008
2008
2008
2008
2009
2009
2009
2009
2010
2010
2010
2010
2011
2011
2012
2012
2012
2012
2013
Age
17
18
18
16
18
0
2
16
18
17
18
16
17
18
18
18
18
18
17
18
18
18
14
16
16
17
17
18
17
17
18
17
17
16
17
18
16
ICD-10 Code
F11 (Mental and behavioural disorders due to use of opioids)
X42 (Accidental poisoning)
F11 (Mental and behavioural disorders due to use of opioids)
F11 (Mental and behavioural disorders due to use of opioids)
F11 (Mental and behavioural disorders due to use of opioids)
PO4 (Fetus and new born affected by maternal factors)
X42 (Accidental poisoning)
F11 (Mental and behavioural disorders due to use of opioids)
F11 (Mental and behavioural disorders due to use of opioids)
Y12 (Poisoning by undetermined intent)
F11 (Mental and behavioural disorders due to use of opioids)
X42 (Accidental poisoning)
Y12 (Poisoning by undetermined intent)
Y12 (Poisoning by undetermined intent)
F11 (Mental and behavioural disorders due to use of opioids)
F19 (Mental and behavioural disorders due to multiple drug 
use and use of other psychoactive substances)
Y12 (Poisoning by undetermined intent)
F11 (Mental and behavioural disorders due to use of opioids)
F11 (Mental and behavioural disorders due to use of opioids)
X42 (Accidental poisoning)
F19 (Mental and behavioural disorders due to multiple drug 
use and use of other psychoactive substances)
Y12 (Poisoning by undetermined intent)
Y12 (Poisoning by undetermined intent)
F11 (Mental and behavioural disorders due to use of opioids)
F11 (Mental and behavioural disorders due to use of opioids)
F19 (Mental and behavioural disorders due to multiple drug 
use and use of other psychoactive substances)
F11 (Mental and behavioural disorders due to use of opioids)
F11 (Mental and behavioural disorders due to use of opioids)
F11 (Mental and behavioural disorders due to use of opioids)
Y12 (Poisoning by undetermined intent)
Y12 (Poisoning by undetermined intent)
X42 (Accidental poisoning)
X42 (Accidental poisoning)
Y12 (Poisoning by undetermined intent)
Y12 (Poisoning by undetermined intent)
X42 (Accidental poisoning)
X42 (Accidental poisoning)
Drug(s) involved
Methadone, Morphine, Cannabis
Methadone, Morphine
Methadone, Diazepam, Alcohol
Methadone, Diazepam, Fluoxetine
Methadone, Diazepam
Methadone
Methadone
Methadone, Diazepam, Alcohol
Methadone, Heroin, Diazepam
Methadone, Alcohol
Methadone, Benzodiazepine, 
Amitriptyline
Methadone
Methadone
Methadone
Methadone, Citalopram
Methadone, Heroin, Amphetamine, 
Ecstasy
Methadone, Dihydrocodeine
Methadone
Methadone, Heroin
Methadone, Diazepam
Methadone, Diazepam, Benzodiazepine
Methadone, Diazepam
Buprenorphine and Diazepam 
Intoxication
Methadone
Methadone
Methadone, Diazepam
Methadone
Methadone
Methadone, Alcohol
Methadone, Diazepam
Methadone
Methadone
Methadone
Methadone
Methadone, Mirtazapine
Methadone, Diazepam
Buprenorphine, Cocaine
Table 3: Total number of methadone and buprenorphine related deaths between 2003 and 
2013 for those up to the age of 18 inclusive, extracted from a dataset provided by the NRS 
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to have been one of accidental poisoning, indicated 
by the corresponding classification code. No further 
information, such as the method of ingestion or to 
whom the methadone was prescribed, was provided.
The majority of deaths (33 of 37) involved 
methadone ingestion by adolescents aged 16 to 
18. Fifteen deaths were attributed to ‘mental and 
behavioural disorders due to use of opioids,’ nine to 
‘poisoning by undetermined intent,’ six to ‘accidental 
poisoning’ and three to ‘mental and behavioural 
disorders due to multiple drug use and use of other 
psychoactive substances.’ As per above, those 
deaths classified as ‘poisoning with undetermined 
intent’ may be classified as ‘probable suicides.’ The 
‘mental and behavioural disorders due to use of 
opioids,’ classification attributed to fifteen deaths 
signifies simply that the person suffered acute 
intoxication due to the use of opioids.56 However, the 
three deaths classified as ‘mental and behavioural 
disorders due to multiple drug use and use of other 
psychoactive substances,’ indicates that there 
was evidence of intoxication caused by recent use 
of other psychoactive substances, or of multiple 
psychoactive substances, where it is uncertain 
which substance predominated.57 It is not known 
whether these teenagers were drug users, although 
the combination of illicit substances in some cases 
may lead to speculation that this is the case. 
One of the deaths recorded in 2005, of a 17 year old 
who died from methadone and alcohol poisoning, 
may be that of Danielle Scott, whose death was 
reported in the media.58 She had mental health 
and behavioural problems, and was known to have 
engaged in drug and alcohol misuse.59 She died 
after taking methadone and alcohol; the methadone 
prescribed to and supplied by a man she’d met that 
day, who later pleaded guilty to a charge of culpable 
homicide. The death of the two year old in 2005 
is presumably that of Derek Doran, who died after 
drinking methadone, thinking it was a soft drink.60  
Both his parents were prescribed methadone, and 
media reports suggest that a child protection inquiry 
was carried out in the aftermath of his death. The 
original report did not include Scottish cases in its 
analysis, given that the system there is governed 
by different guidance; however, media reports were 
reviewed, which did identify Derek Doran’s death. No 
more information relating to the deaths in Table 3 
could be sourced from media reports.
In seeking to obtain more information about each 
individual death, the Crown Office Procurator 
Fiscal Service (COPFS) was provided with the 
statistics obtained by the NRS, and a request for 
information relating to these deaths was made 
under the Freedom of Information (Scotland) Act 
2002.61 COPFS confirmed that the 35 methadone-
related deaths had been reported, but failed to 
provide relevant information on any case. The 
COPFS routinely remove cases over five years old 
from their system, and stated that four of the 35 
56  WHO (no date published) ‘The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic criteria for research’ (Web resource) 
57  Ibid
58  BBC News (29 August 2006) ‘Addict admits methadone killing’ (Web resource)
59  Judiciary of Scotland (30 July 2009) Sheriffdom of Lothian and borders at Edinburgh, Sheriff John Horsburgh (Web resource)
60  Edinburgh News (6 March, 2006) ‘Methadone toddler ‘wasn’t on at risk list’ (Web resource)
61  Child drug-related deaths are reviewed by committees that sit within health boards in Scotland. The committee then reports these deaths to the Scottish Fatalities Investigation Unit,  
a unit within the Crown Office Procurator Fiscal Service (COPFS).
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group of poisons most commonly used (14 cases), 
and opiates were the second most common (8). 
Whether these opiates were prescribed or not is not 
commented upon. 
The authors note that these forms of abuse are rare 
– the combined annual incidence in children under 
16 was found to be 0.5/100,000, and for children 
under 1, at least 2.8/100,000. Yet, it is also stated 
that, as is common in many epidemiological studies, 
these calculations are likely an underestimation, 
and that these forms of abuse are underreported. 
While the three forms of abuse were found to be 
closely related, the authors concluded that it is 
unusual for non-accidental poisoning to occur 
alone. This research, however, primarily focuses on 
forms of abuse and intent to cause harm to the child. 
There is no evidence in SCRs or available literature 
to suggest that those cases that were deemed to 
have involved parental administration were driven 
by the parent’s desire to cause harm to the child. 
Rather, SCR evidence suggests that OST medication 
is administered to pacify, rather than deliberately 
harm the child.
One piece of German research sought to determine 
the extent to which children living with drug-
using parents are in danger of poisoning from 
methadone and illegal drugs.64 An analysis of hair 
samples from 149 children (aged 1-14) living with 
parents receiving a methadone prescription and/or 
suspected of misuse of illegal drugs, and from 124 
of the parents was conducted. Only in 35 samples of 
cases were no longer held. It would not release 
sensitive information on the remaining files due to 
confidentiality requirements, or because it did not 
consider the information to be in the public interest.
6. The prevalence of intentional 
administration
The lack of research on the prevalence of intentional 
administration of OST medications to children by 
parents or carers is in urgent need of rectification. 
Our knowledge of the incidence of this practice, 
together with an understanding of the driving 
factors and motivations behind it, is one of the most 
considerable gaps this research has identified. 
Whilst it does consider OST specifically, a piece 
of research from 1996 sought to determine the 
epidemiology of Munchausen syndrome by proxy,62
non-accidental poisoning and non-accidental 
suffocation in the UK and the Republic of Ireland 
over a two-year period.63 A total of 128 cases 
were identified: 55 suffered from Munchausen 
syndrome by proxy, 15 poisoning, 15 suffocation 
and 43 suffered more than one type of abuse. The 
majority of the children were aged under five – the 
median age being 20 months – and prior sibling 
abuse was not uncommon. On 85% of occasions, 
the perpetrator was the child’s mother, and eight 
children were known to have died as a direct 
result of their abuse, all from either poisoning or 
suffocating. The study identified 44 cases where 
a child was intentionally poisoned, 71% of which 
involved prescribed drugs. Anticonvulsants were the 
62  A form of child abuse whereby parents or carers fabricate childhood illnesses.
63  McClure et. al. (1996) ‘Epidemiology of Munchausen syndrome by proxy, non-accidental poisoning and non-accidental suffocation,’ 75(57) Archives of Disease in Childhood 61
64  Pragst et.al. (2013) ‘Methadone and illegal drugs in hair from children with parents in maintenance treatment or suspected drug abuse in a German community,’ 35(6) Ther Drug Monit. 737
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their children. SCR evidence, and anecdotal evidence 
from the treatment population (as reported by several 
professionals over the course of this research), 
suggests that the practice of parental administration 
of drugs to children is not as uncommon as one may 
hope, and early findings reported from this research 
corroborate this. 
Our review of SCRs identifies a number of methods by 
which children come to ingest drugs (both prescribed 
and illegal) in the home, including through passive 
ingestion (e.g. inhalation of smoke) 67 and intentional 
administration for the purpose of pacification; 
yet, these possibilities are rarely recognised or 
accounted for. The fact that SRCs very often do not 
analyse the event of ingestion itself, and rarely make 
recommendations which address it,68 presents an 
additional obstacle to raising awareness of intentional 
administration, and forming appropriate and effective 
policies to guard against this risk.  Those that have 
made recommendations suggested that local areas 
take action to determine how commonplace a practice 
this may be amongst its OST-prescribed population, or 
to highlight the risks of giving children methadone.
7. The relative safety of methadone and 
buprenorphine
Research has tended to focus on the comparative 
effectiveness of methadone and buprenorphine at 
retaining clients in treatment, suppressing cravings or 
reducing illicit opioid use; meanwhile, very little has 
been done to examine their relative safety. However, 
children’s hair were no drugs detected. Methadone 
was identified 35 times, with additional use of illegal 
drugs indicated in 28 of these cases. It also found 
that drug use in the children’s environment was 
obvious for a range of illegal drugs; with cocaine, 
cannabinoids and heroin, in that order, being the 
most common.65 Hair strands from younger children 
generally contained higher concentrations than 
from elder siblings. The authors discussed several 
possible explanations for the incorporation of 
drugs into the hair, including from smoke, through 
contact with contaminated surfaces or parent’s 
hands, after passive smoking, administration or 
oral intake by hand-to-mouth transfer. Evidence of 
‘systemic incorporation’66 of methadone, as well as 
illegal drugs, was found. The authors concluded that 
investigation of children’s hair proved a useful way to 
detect ‘endangering drug use in their environment,’ 
and to lead to a more thorough inspection, and 
measures to improve their situation in many of the 
cases. Whilst this research suggests that children 
whose parents receive OST or use illegal drugs are 
likely to be exposed to drugs in the home, it does 
not show how many of these involved deliberate 
administration by the parents. 
Whilst requesting evidence of current ways of 
working from local authorities, Adfam became aware 
of a public health practitioner, based in England 
and specialising in substance use, undertaking 
research into the incidence amongst the general 
population of parental administration of drugs to 
65  In terms of illegal drugs, cannabinoids were found in 56 samples, and drug use in the children’s environment was obvious for heroin in 44 cases, cocaine in 73 cases, amphetamine or 
ecstasy in 6 cases and diazepam in 8 cases.
66  This signifies that children were systematically exposed to the drug over a period of time, but does not prove that the drug was intentionally administered to the child by a parent/caregiver. 
67  Toxicology tests sometimes showed exposure to a variety of drugs over a length of time; which was thought, presumably, to have been as a result of passive ingestion through inhalation 
or contaminated environments.
68  This is discussed in greater detail in Section Three.
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The report cites the NICE guidance recommending 
methadone as the preferred option where both 
drugs appear equally suitable, and states that the 
substantial difference in risk between the two 
drugs highlighted by these findings, together with 
previous reports of fatalities, means the treatment 
sector ‘may need to reappraise its relationship with 
methadone.’ Furthermore, the authors highlight the 
challenges facing clinicians when deciding whether 
a person is complying – and is able to maintain 
compliance – with treatment, given that the identified 
risk of methadone diversion makes potential safety 
implications for persons other than the individual 
patient difficult to judge. Indeed, the risk of diversion 
is well established: a Danish piece of research71  into 
drug-related deaths between 2008 and 2011 found 
that only 44% of persons with toxicology findings of 
methadone were in opioid substitution therapy and 
receiving methadone at the time of death. Findings 
from English data in 2013 similarly showed that just 
32.5% of the 256 people who died of methadone-
related causes were known to be receiving a 
prescription for methadone – 67.5% were not.72 
Ultimately, the report recommends that the risk of 
diversion and significant risk differentials between 
methadone and buprenorphine should inform 
individual treatment decisions, as well as treatment 
guidelines. 
The significance of the study, however, should 
not be overstated: it is an observational piece of 
a study conducted in England to assess the relative 
risks of methadone and buprenorphine was published 
during the writing of this report.69
Drawing mortality data from the ONS and methadone 
and buprenorphine prescription data from the NHS, 
the research sought to examine the population-
wide overdose risk emerging from the prescription 
of methadone and buprenorphine for OST. In the 
period under review (2007-2012), it found that there 
had been 2,366 deaths related to methadone, and 
52 to buprenorphine. This corresponded to 17.3 
million methadone and 2.6 million buprenorphine 
prescriptions issued: the number of methadone 
prescriptions being seven times greater than the 
amount of buprenorphine prescriptions. These 
figures include deaths across all age groups, and 
of people both prescribed and not prescribed the 
medication, but the report does not consider risks 
to children specifically. The relative risk ratios of 
methadone and buprenorphine, by substance-specific 
overdose rate per 1,000 prescriptions issued, was 
calculated; showing the pooled overdose death rate 
as 0.137/1000 for methadone, and 0.022/1000 for 
buprenorphine (including buprenorphine-naloxone). 
This led to the finding that ‘buprenorphine is six times 
safer than methadone with regard to overdose risk 
among the general population,’ causing the authors 
to conclude: “Clinicians should be aware of the 
increased risk of prescribing methadone, and tighter 
regulations are needed to prevent its diversion.”70  
69  Marteau, McDonald and Patel (2015) ‘The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales,’ BMJ Open (Web resource)
70  Ibid
71  Tjagvad et. al. (2014) Drug-induced deaths and other drug related deaths in Denmark, 2008-2011. (Web resource). See also: Heinemann et. al. (2000) ‘Methadone-related fatalities in 
Hamburg 1990-1999: implications for quality standards in maintenance treatment?’ 113(1-3) Forensic Sci Int 449
72  Claridge & Goodair (2015) ‘Drug-related deaths in England, Northern Ireland, The Channel Island and the Isle of Man: January-December 2013,’ National Programme on Substance Abuse 
Deaths (NPSAD), St George’s, University of London
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all-cause mortality was lower for buprenorphine 
than methadone. In the four weeks after treatment 
cessation, all-cause mortality did not differ, and drug-
related mortality was lower for methadone. An earlier 
study, which sought to investigate the effect of OST 
at the different stages of treatment and according to 
its duration, similarly found no variance in the risk of 
death between buprenorphine and methadone when 
comparing the whole period on and off treatment.79
However, this study solely considered all-cause 
mortality, and did not look at the quality of the 
different interventions provided. 
A recent guideline for the use of OST medications 
in treatment, published in the USA,80 recommended 
further research into the comparative advantages of 
the different drugs used in OST; stating that whilst 
methadone, buprenorphine and other drugs used in 
the treatment of opioid dependence have been proven 
to be superior to receiving no treatment, much less is 
known about their relative advantages to one another. 
Given the disparity between the number of child 
deaths and hospitalisations related to methadone 
compared to buprenorphine, a deeper analysis of 
the respective risks, whilst accounting for relevant 
variables, should be carried out.
research, in that it does not evidence causal links. 
The paper acknowledges its limitations: one being 
that the complexity of the client is not accounted 
for in the data and, thus, it is not possible to 
identify potential differences in the severity of drug 
dependence between clients prescribed methadone 
and buprenorphine. Research suggests that clients 
prescribed methadone are more likely to be complex 
than those prescribed buprenorphine.73 In which 
case, the mortality risk amongst those prescribed 
methadone as opposed to buprenorphine would likely 
be higher.74 However, evidence from a 2009 study75  
supports the above finding that buprenorphine 
carries less risk of mortality, whilst a French 
study reported that opioid overdose deaths had 
declined in France by 79% since the introduction of 
buprenorphine nine years earlier.76 / 77
A retrospective cohort study of service users in New 
South Wales78 compared crude mortality rates for 
methadone and buprenorphine for all-cause and 
drug-related overdose mortality. It found that whilst 
patients who began treatment with buprenorphine 
had reduced all-cause and drug-related mortality 
during the first few weeks of treatment, compared 
with those who started with methadone, for the 
remaining time on treatment, drug-related mortality 
risk did not differ. ‘Weak’ evidence suggested that 
73  Marsden et. al. (2014) ‘Development of the Addiction Dimensions for Assessment and Personalised Treatment (ADAPT)’ 139(1) Drug Alcohol Depend 121
74  The method by which the number of doses of buprenorphine prescribed is also based on a mean estimate, derived from data from a small sample size of 14 treatment services that 
responded to the request for data. Despite this, the assertion that buprenorphine is six times safer is precise, and one may have assumed a wider range of values would be proposed e.g. ‘three 
to nine times safer.’
75  Bell et. al. (2009) ‘Comparing overdose mortality associated with methadone and buprenorphine treatment,’ 104(1-2) Drug Alcohol Depend 73
76  Auriacombe et. al. (2004) ‘French field experience with buprenorphine,’ 13 Am J Addict 17
77  See also: Auriacombe et. al. (2001) ‘Deaths attributable to methadone vs. buprenorphine in France,’ 285(1) Am Med Assoc
78  Kimber et. al. (2015) ‘Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study,’ The Lancet Psych 
79  Cornish et. al. (2010) ‘Risk of death during and after opiate substitution treatment in primary care: prospective observational study in the UK General Practice Research Database,’ BMJ 341
80  Kapman and Jarvis (2015) ‘American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use,’ 9(5) 
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of child deaths attributed to OST medications during 
that period. Indeed, between 2003 and 2013, at 
least 110 persons aged 0-18 died from methadone 
or buprenorphine poisoning in the UK. This only 
includes one of the deaths in the English and Welsh 
data relating to buprenorphine poisoning, given that 
we do not know how many of the 19 deaths recorded 
involved under-18s, with the exception of one; with 
which the SCR was able to be cross-referenced. 
However, it is unlikely that this was the only death 
involving a person aged 18 or under. The data from 
England and Wales shows that of the 72 methadone-
related deaths involving persons up to the age of 18 
inclusive, only six resulted in a SCR. This means that 
an additional 66 deaths did not lead to a SCR. We do 
not know the proportion of deaths in Scotland that 
resulted in a significant case review.
The hospital admissions statistics add to this startling 
picture of the reality of OST ingestion in children: 
at least 310 children under 18 were admitted to 
hospital with methadone poisoning between 2003 
and 2013, and a further 18 in 2013-14. Again, this 
is an underestimation, since for much of this period 
the HSCIC’s breakdown of age did not allow for 
distinction between children aged 15 and above 
and adults, and statistics on the number of children 
admitted to hospital with buprenorphine poisoning 
were not available. The data also relates only to 
England, thus it may be assumed that more children 
have been hospitalised due to OST drugs in the UK 
over this period.
The number of methadone prescriptions in England 
and Wales has gradually decreased over recent years, 
following a peak of 3.1 million in 2010,81 whilst 
the proportion of buprenorphine to methadone 
prescriptions has increased from 14% in 2007, 
to 18% in 2012. The number of buprenorphine 
and buprenorphine-naloxone  prescriptions 
dispensed in England and Wales has also risen, with 
buprenorphine-naloxone82 having accounted for 
0.4% of all prescriptions in 2007, and 2.6% in 2012. 
Whether this increase is driven by a growing belief 
in the greater safety of the drug in comparison to 
methadone is not reflected upon in the research.
8. Conclusion
Ascertaining an estimate of the true number of child 
ingestions of OST medications proved challenging in 
the original report: there was no publicly accessible 
data on the number of ingestions, fatal or otherwise. 
The most reliable method, albeit recognised as 
limited, was to collate SCRs involving child ingestions 
of OST drugs, which revealed 23 ingestions and 17 
fatalities in the period between 2003 and 2013. 
Given that not all deaths will result in a SCR, and that 
SCRs will not provide an indication of the number of 
‘near misses’, it was acknowledged that using SCRs 
as a way of measuring the incidence of child OST 
ingestions would provide an inadequate snapshot of 
the scale of the problem. 
Taking this new data from all four countries of the UK 
together, it is evident that the 17 deaths uncovered 
by the SCRs constitute a fraction of the total number 
81  Marteau, McDonald and Patel (2015) ‘The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales,’ BMJ Open (Web resource)
82  Bupenorphine-Naloxone is a combination medication used to treat opioid dependence and prevent withdrawal. Often referred to by its brand name, Suboxone.
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absence of a SCR or further information relating 
to these deaths, the respective number of cases of 
parental intentional administration and accidental 
ingestion cannot be ascertained, nor can we know to 
whom the methadone was most commonly prescribed 
or on what regime i.e. supervised consumption or 
take-home doses. This evidence is therefore limited 
in terms of what it can tell us about patterns of child 
ingestions; and consequently, what to prioritise in 
terms of policy and practice around safeguarding 
children from the risks posed by OST medications. 
To address this, the government should have 
consideration for the adoption of national standards 
for reporting of child ingestions of OST medications, 
and clarification on SCR thresholds.
The finding that buprenorphine carries significantly 
less overdose risk for the general population 
than methadone is worthy of attention, and has 
been supported by several other research study 
findings. Despite the fact that none considered the 
risks to children specifically, such evidence of the 
comparative mortality risks between methadone and 
buprenorphine should nevertheless be borne in mind 
by clinicians when assessing the respective suitability 
of the drugs for all clients, especially those in contact 
with children. 
The application of NICE guidance advising that 
methadone should be prescribed in cases where 
both methadone and buprenorphine appear ‘equally 
suitable’, may have resulted in methadone becoming 
the ‘default’ option, with insufficient consideration 
given to the risks to children. Such clinical practice 
A further distinction that can be drawn from the 
findings of the original report is that of the age of 
the children. The cases of child ingestions reported 
in SCRs suggested an age bias towards very young 
children: recall that the median age of children 
subject to the SCRs was just two. However, it seems 
from the mortality statistics that the majority of 
children ingesting OST medications are adolescents; 
although, we do not know how they came to access 
the medication or the circumstances around 
the ingestion itself. The data from Scotland may 
suggest that some of these adolescents were drug 
users (given the classification code or mixture of 
substances found in the body), and that others took 
the drug in a suicide attempt, but in the absence of 
further information – or indeed a SCR – the precise 
circumstances are unknown. We know methadone 
is commonly misused amongst adults,83 and the 
Scottish data and SCR evidence suggests that 
adolescent deaths attributed to OST medications are 
often linked to drug use or suicide, but this cannot 
be confirmed against the data available. In light of 
this new evidence, further research into how and why 
adolescents are coming to ingest methadone and 
buprenorphine is needed to inform work to reduce 
fatalities in this group. 
The reason why these additional deaths and 
ingestions did not lead to a SCR is not known. It is 
open to speculation whether this is as a result of 
varying thresholds in local authorities, or differences 
in the facts of the cases, such as a lack of professional 
involvement or suspected abuse or neglect. In the 
83  Marteau, McDonald and Patel (2015) ‘The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales,’ BMJ Open (Web resource)
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should be reassessed in light of this new evidence, 
and clinical guidance should clarify precisely under 
what circumstances methadone and buprenorphine 
may not be equally suitable for a client. It is hoped 
that the revision of the ‘Orange Book’ clinical 
guidelines, expected next year, will provide greater 
clarity.84 In addition, the cost implications often cited 
as a reason for methadone being prescribed may 
suggest the need for commissioners to complete a 
cost-benefit analysis, to include differences in risk of 
overdose and death in children and adults.85 However, 
it must not be forgotten that treatment in itself offers 
a protective factor for the child.86 Whilst safeguarding 
children must be the primary concern of professionals 
working with the family, it is also important to 
ensure that parents in treatment feel sufficiently 
supported and are provided with suitable and agreed 
recovery or care plans, to maximise the probability of 
engagement with treatment. 
84  Details of Adfam’s contribution to the consultation of these guidelines is discussed in Section Four
85  This may become even more pressing given the continuing cuts to Public Health budgets.
86  Adfam (2014) Medications in Drug Treatment: Tackling the risks to children
Section three: 
Serious Case Reviews
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have received custodial sentences. The main points to 
draw from these cases are discussed below.
 — Safe storage
In neither case was the methadone stored safely in the 
home: in ‘Child BT’s’ case, the methadone was found 
in children’s feeding cups and fruit juice bottles, and 
in ‘Child H’s’ case, it was left in a room with the child, 
unsupervised. In the latter, the mother was on a daily 
pick-up dispensing regime: she reportedly left the 
methadone in a child-resistant bottle in her handbag, 
left the room and ‘Child H’ then drank the contents. It 
is not discussed in the overview report how a child was 
able to open a child-resistant cap; which is, according 
to the WHO and UNICEF, one of the best-documented 
successes in preventing accidental poisoning in 
children.90 Standards for child resistant packaging 
require that it should be tested by asking a group of 
children aged between 42 and 51 months to open a 
pack. If they have not opened it within five minutes, 
they are shown how to open it and given another five 
minutes to try again. At least 85 per cent of children 
should be unable to open the child resistant packs 
within the first five minutes, and at least 80 per cent 
still unable following the demonstration.91 Whilst 
this suggests that child resistant packaging is mostly 
very effective, the BSI92 admits that no container 
designed for everyday use can be ‘guaranteed to be 
totally child-proof,’ and highlights the importance of 
further safety precautions with dangerous products, 
including keeping medicines out of the reach of 
Serious case reviews are intended to provide an 
opportunity for agencies and individuals to learn 
lessons and to improve their methods of working, 
in order to effectively safeguard and promote the 
welfare of children.87 Since the publication of the 
original report, three more SCRs involving OST 
ingestions by children in Blackpool, Birmingham and 
Oxfordshire have come to light. As of October 2015, 
the Birmingham review had not yet been published, 
although the facts of the case were found in media 
reports.88  The facts and findings of Blackpool’s ‘Child 
BT’ (2015) and Oxfordshire’s ‘Child H’ (2014) SCRs bear 
striking resemblance to those of the SCRs examined 
in the original report. Serious case reviews identify 
opportunities for learning and make recommendations 
to prevent similar incidents occurring in the future. The 
‘Child H’ overview report also contains a list of changes 
implemented as a result of the case. The full overview 
reports are accessible via the NSPCC’s national 
repository of serious case reviews.89
1. Summary of facts, findings and 
recommendations 
The facts of the two published serious case reviews are 
similar: both involve a child’s ingestion of methadone 
(‘Child BT’ was two years old and ‘Child H’ 21 months), 
which was prescribed to the mother and deemed to 
have been accidentally ingested by the children. One 
ingestion proved fatal (Blackpool, ‘Child BT’), whilst 
the other child made a full recovery (Oxfordshire, ‘Child 
H’). The parents of ‘Child BT’ and the mother of ‘Child H’ 
Section three: Serious Case Reviews
87  Department for Children, Schools and Families (2010) Working together to Safeguard Children Chapter 8: Serious Case Reviews
88  The Mirror (5 March, 2015) ‘Fenton Hogan: Serious Case Review launched into tragic toddler’s death.’ (Web resource)
89  NSPCC National case review repository. Available at: http://www.nspcc.org.uk/preventing-abuse/child-protection-system/case-reviews/national-case-review-repository/ 
90  BSI Group (date unpublished) Child resistant packaging: A consumer’s guide to the standards for child resistant packaging. (Web resource)
91  Ibid
92  BSI is the UK National Standards Body which develops standards to make products and services safer for consumers. Standards set out good practice and guidelines for organizations to 
follow. BSI is the UK member of European standards organization CEN.
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“Despite the complexity of their daily lives, Child BT’s 
family did not stand out as unusual to professionals 
who see many similarly complex families in 
Blackpool.…Other serious case reviews have shown 
that when professionals work with many similarly 
complex families it can result in them becoming 
less perceptive to the level of complexity and the 
associated risk and impact over time.”
The extent to which professionals understood the 
thresholds for statutory intervention, and what 
constituted significant harm, was also found to be 
inconsistent, and appropriate action was not always 
taken.
An insufficient appreciation of risk was likewise 
identified in ‘Child H’s’ case. In particular, the health 
visitor was deemed to have ‘little knowledge about 
the impact on parenting of drug use or the risks 
associated with being on methadone and did not 
consider it her role to address the safe storage of 
methadone.’ The review panel stated that because 
health visitors in the area worked with many 
substance users, she should have accessed training 
available through the LSCB. The normalisation by 
professionals of ‘aberrant’ behaviours was highlighted 
in the review, and the mother’s dishonesty was 
found to have been accepted without challenge. The 
overview report stated that children’s social care had 
since introduced mandatory toolkits covering neglect 
and substance misuse, and were undertaking work 
to clarify expectations of a ‘team around the child,’ 
in response to the case. Recommendations included 
children, always storing chemicals in their original 
containers and safe disposal.93
In contradiction to this advice, the parents of ‘Child 
BT’ were found to have been selling the methadone 
prescribed to the mother, to a buyer who wanted it 
sold in the original bottle. This was the explanation 
provided by the mother as to why the methadone had 
been stored in various receptacles around the home, 
although this justification is not explained in the SCR 
report. 
Safe storage was reportedly discussed with the 
client in the two cases, although ‘Child BT’s’ mother 
denied ever having been given advice on safe 
storage or provided with a lockable box. In the case 
of ‘Child H’, the health visitor was considered to 
have drawn an ‘arbitrary distinction’ between the 
issue of safe storage and the hazards represented 
by other household materials, and did not consider 
it within the scope of her role to check on storage 
arrangements. It was recommended to the health 
visiting service that the issue of safe storage be 
included in discussions about accident prevention.
 — Parental substance use
In Child BT’s case, it was suggested that because 
professionals in the area had a significant number of 
problem drug users on their caseloads, professionals 
potentially normalised chaotic or risky behaviours; 
therefore overlooking the ‘signs, symptoms and 
safeguarding issues associated with problem drug 
use.’ The panel stated: 
93  Ibid
46 Medications in Drug Treatment: Tackling the risks to children - one year on
Furthermore, he would not agree to a Common 
Assessment Framework (CAF)94 – the standardised 
approach to conducting an assessment of a child’s 
needs and deciding how they should be met – 
and this was accepted without challenge. It was 
known that ‘Child BT’s’ mother was not consistently 
complying with treatment, by using illicit drugs; 
yet sufficient action was not taken and no whole 
family assessment was carried out. The review 
panel asserted that drug services should be able to 
recognise the features of non-compliance (such as 
providing ‘false’ urine samples), and recommended 
that ‘all drug-using parents be drug tested via swab 
tests if this is a more accurate and reliable test result.’ 
Drug services must also acknowledge, it stated, that 
‘there is a market for the purchase of methadone.’ 
‘Child BT’s’ mother and father, when interviewed as 
part of the review process, both commented on the 
over-optimism of professionals working with the 
family. 
Throughout the period of the ‘Child H’ review, 
many instances of parental deceit and disguised 
compliance were observed. The mother hid her 
involvement in criminal activities – which included 
selling and using illicit drugs – and lied about 
appointments, her methadone dosage, whereabouts, 
‘Child H’s’ attendance at children’s centres and 
arrests.
The ‘Child BT’ review panel recommended that 
non-compliance result in immediate action to bring 
multi-agency professionals together to discuss 
training health visitors and the police, to highlight 
the impact of parental substance use on the ability to 
parent.
Adfam’s original report recommended that, in order 
to ensure that parental substance use is adequately 
prioritised in the local agenda, drug practitioners 
should be represented on the LSCB and review 
panels for cases involving parental substance use. 
It is stated in the ‘Child H’ overview report, having 
cited Medications in Drug Treatment, that the need 
for ‘further expertise’ on the panel was recognised, 
which led to the appointment of a commissioning 
manager for the public health drug and alcohol 
action team. The ‘Child BT’ panel also included 
representation from drug treatment professionals. 
This is encouraging, and drugs workers should 
continue to be represented on future review panels in 
all cases where parental substance use is a factor. 
 — Professional curiosity and challenge
A common finding between the cases was that 
professionals working with the family were overly 
optimistic, with a ‘tendency to accept at face value 
the [mother’s] claims’ (‘Child H’). The parents of 
‘Child BT’ had been selling methadone, which was 
prescribed to the mother, for some time. This may 
have gone unnoticed given that ‘Child BT’s’ father 
rarely participated in discussions about the children’s 
health and wellbeing, and would frequently excuse 
himself when professionals visited the home. It was 
known that ‘Child BT’s’ father had a long history of 
drug use and was potentially vulnerable to relapse. 
94  A multi-agency package of support put in place to help families who may be struggling for a variety of reasons.
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visitors would initiate contact on behalf of the practice, 
presumptions by GPs and drugs workers that the other 
would initiate a conversation ‘if need be’ and the health 
visitor’s assumption that ‘her role was to look forward 
not back (and avoid any discussion about drugs).’ 
The panel stated that pharmacists need to be reminded 
of the expectation that children’s services and/or the 
police should be informed if they are concerned a 
client poses a risk to their child, and recommended 
that the police conduct a scoping exercise into the 
viability of making routine referrals to children’s 
services about parents or carers with substance misuse 
issues. It also stated that the LSCB should encourage 
commissioners of GP services and public health 
commissioners to review their monitoring processes, 
in order to ensure collaborative management of 
contracted services provided in general practice, 
especially drug and alcohol services. Overall, an 
‘inward focus’ was identified: agencies focused too 
narrowly on their own particular role, and assumed 
that other agencies would initiate communication 
should a problem or concern arise.
Since then, children’s social care in Oxfordshire is 
reported to have started routinely monitoring and 
reporting the attendance rates of partner agencies at 
child protection conferences and ‘core groups.’ The 
harm minimisation service also incorporated a system 
of audit of clinical practice, to provide an accurate 
picture of the quality of practice and to identify trends 
or issues in joint-working. In neither of these cases did 
an agency or professional take the lead in working with 
the family.
the case, and that safeguards, such as supervised 
consumption, be put in place to reduce the potential 
for disguised compliance.
 — Joint-working and information-sharing
During the periods under review, both families were 
in contact with a number of services, including 
health visiting, children’s social care, drug services, 
police, GPs and hospital services. Again, the review 
panels found that information-sharing amongst the 
agencies involved with the family was generally of 
‘variable quality and consistency’ (‘Child BT’). The 
panel in ‘Child BT’s’ case found that robust systems 
and processes for sharing information were absent, 
and that inter-agency working to safeguard children 
of problem drug users needs to be strengthened. 
In the case of ‘Child H’, the review panel acknowledged 
the ‘good deal of inter-agency information exchange,’ 
but indicated a number of strategic obstacles to 
‘achieving a clear and complete picture across the local 
agency network,’ including a lack of contact between 
the GP and health and other colleagues, as well as 
the GP’s failure to respond to repeated requests for 
information from the hospital service. The fact that the 
child was subject to a child protection plan was judged 
not to be sufficiently visible on the police force’s 
databases and systems, and there was an ‘unjustified’ 
reluctance to share intelligence by the police, with 
children’s social care, about the mother’s ‘drug-related 
lifestyle.’ The review additionally found evidence of 
‘unjustified presumptions’ by professionals about what 
colleagues in other agencies would, or should, be 
doing. This included presumptions by GPs that health 
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not involved, and the second case did not involve an 
ingestion but a ‘near miss.’ The news report suggests 
that the police were not informed nor was Plymouth 
City Council said to be aware of the incident. The 
person to whom the Subutex was prescribed and the 
reason for its being in the playground is unknown. 
Whilst the scope of this research is limited to drugs 
used in OST, it is also worth considering a SCR99  
involving a 23-month old child’s death from a heroin 
overdose, based on the striking similarity of the 
facts, findings and recommendations of the case to 
the SCRs considered as part of this research. The 
child reportedly died after swallowing a ‘wrap’ of 
heroin, although toxicology tests showed that he 
had been regularly exposed to a number of illegal 
substances over time (suggesting passive ingestion 
through, for example, inhalation or a contaminated 
environment). Both parents had been in receipt of 
a methadone prescription, and the family was in 
contact with a range of services. The review found 
that despite 11 multi-agency child in need meetings, 
relevant information was not always shared, and 
there were many ‘missed opportunities.’ The parents’ 
engagement with services was patchy, and there 
was insufficient enquiry by practitioners about 
the parents’ drug use and their consideration of 
the child’s safety. The panel concluded that had 
practitioners exercised greater professional curiosity 
and been more assertive with the family, the death 
may have been avoidable. Recommendations focused 
on improving safeguarding risk assessments, 
2. Other cases
As noted above, Adfam was alerted to the 
undertaking of another SCR, involving the ingestion 
of OST medication by a child in Birmingham, Fenton 
Hogan. Since the review has yet to be published, 
the facts of the case have been sourced from media 
reports; according to which, a 23-month-old child 
died after being administered methadone by his 
mother, in order to help him sleep.95 Methadone 
bottles were found lying around the home, and the 
child’s mother was served a custodial sentence for 
manslaughter. As is common in media reporting on 
such cases, the focus lay on the criminal proceedings 
brought against the parent, and lacked any real 
analysis of policy and practice considerations of OST 
and safeguarding. 
Local news reports also revealed that a two year 
old in Plymouth was hospitalised after finding a 
wrapper containing Subutex96 in a playground and 
swallowing it, thinking it was a sweet.97 The toddler 
made a full recovery, and the article contained no 
further information specific to OST; stating simply 
that Subutex is used to treat heroin dependence. 
A similar incident, where a methadone bottle 
containing approximately a tenth of its original 
contents was found in a children’s play area, has 
also been reported.98 These incidents differ from the 
other cases considered as part of this research, in 
that the drug was found on the floor of a playground, 
and was not prescribed to the child’s parents. No SCR 
will be conducted, given that abuse or neglect are 
95  The Mirror (5 March, 2015) ‘Fenton Hogan: Serious Case Review launched into tragic toddler’s death’ (Web resource)
96  Subutex is the brand name for buprenorphine.
97  The Herald (9 September, 2015) ‘Toddler ate heroin substitute in Plymouth playground thinking it was sweets’ (Web resource)
98  Edinburgh News (11 December, 2012) ‘Methadone bottle found at children’s play area’ (Web resource)
99  Wolverhampton, ‘Daniel’ (2013)
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not consider it her responsibility to check on safe 
storage. The panel stated that she should have 
accessed training via the LSCB; which suggests 
that whilst training for health visitors on parental 
substance use was available, she had not undertaken 
it. The panel consequently recommended a review 
of health visiting training needs in relation to 
parental substance use and its impact on parenting. 
Consideration should be given to the mandatory 
training of multi-disciplinary professionals in areas 
where there are a large number of substance users, 
and efforts must be strengthened to encourage all 
professionals to realise their responsibility to protect 
and safeguard children. One method of ensuring 
that SCR learning is disseminated at least locally 
was endorsed by the panel in the ‘Child H’ case 
(after having been proposed by the local clinical 
commissioning group which participated in the 
review process): that summaries of SCRs should be 
circulated in local newsletters and briefings, and 
training events should include a section on SCR 
learning.
SCRs have been subjected to criticism, including 
for having ‘too much emphasis on getting the 
process right, rather than on improving outcomes 
for children.’100 Some reviews have also been 
criticised for concluding that harm to children was 
not predictable, despite obvious warning signs.101 It 
is not the aim of this report to assess the quality of 
individual SCRs, or comment on the efficacy of the 
system overall. It is important to note, nonetheless, 
that SCRs do not always aim to discuss the details of 
inter-agency working and collaboration, workforce 
knowledge and competency, recognising the impacts 
of parental substance use and ensuring a family 
focus. 
3. Conclusion
The features of these cases are all too familiar; and 
many of the conclusions reached in the original 
report should be reiterated. The bias towards younger 
children remains apparent, as does the practice 
of unsafe storage of drugs in the home and an 
insufficient appreciation of the dangers of OST drugs 
to children. In the ‘Child BT’, ‘Child H’ and the (as 
yet unpublished) Birmingham SCRs, the methadone 
was prescribed to the mother. The families subject 
to these reviews were in contact with a range of 
different agencies, and recommendations again 
focused on improving information-sharing, inter-
agency collaboration, professional awareness of the 
risks associated with OST, recognising disguised 
compliance and the professional tendency towards 
over-optimism. The review panel in ‘Child H’ made 
reference to Adfam’s conclusion in the original report; 
that the frequency and similarity of cases involving 
child ingestions of OST drugs shows that learning 
from these cases is not taking place.
The need for this learning to be shared to prevent 
future incidents of child ingestions and raise 
awareness of the risks of OST medications to children 
thus remains. The health visitor in ‘Child H’s’ case 
was found to be insufficiently aware of the risks of 
methadone and its impact on parenting, and did 
100  Professor Eileen Munro (2011) Munro Review of Child Protection: A child-centred system
101  See, for example, The Guardian (November 13th 2013) ‘Hamzah Khan: Minister has ‘deep concerns’ over review findings’ (Web resource)
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analysis’ in the report focused solely on practice, and 
the event (the ingestion) which caused the child’s 
death was not analysed. Nowhere in the report was 
consideration given to further exploration of why 
methadone was found in a child’s cup, or whether 
there was a possibility of intentional administration. 
This may indicate a lack of awareness of the practice, 
and subsequent consideration by professionals. 
Research to uncover more information about the 
prevalence of parental administration of medications 
to their children is vitally needed. 
A summary of the most common recommendations 
of SCRs involving child ingestion of OST medications 
would place the necessity of effective joint-working 
and strong information-sharing at its core. ‘Missed 
opportunities’ identified in these cases are often 
related to a lack of communication amongst 
professionals working with the family, and efforts 
to strengthen local joint-working are imperative to 
an effective safeguarding policy for children whose 
parents or carers are prescribed OST drugs. It is 
unlikely that any one change could have prevented 
these incidents; rather, a much more strategic, 
coordinated response is required. This could be 
facilitated by effective mechanisms for sharing the 
learning from individual SCRs, locally and nationally, 
and a national review of SCRs to identify trends and 
patterns. 
a single event in which a child has come to harm, but 
focus on investigating the professional engagement 
with the family, with a view to learning lessons and 
identifying areas which could be improved to reduce 
the risk of future incidents. Whilst this is, of course, 
important, research undertaken by what was then the 
Department for Children, Schools and Families found 
that ‘local overview reports often provided insufficient 
information to achieve a clear understanding of the 
case and the incident which led to the children being 
harmed or killed.’102 This could lead to limitations 
when trying to improve policy and practice to prevent 
children coming to harm. The role of the Association 
of Independent LSCB Chairs in England, the Scottish 
Child Protection Committee Chairs Forum, the 
Safeguarding Board for Northern Ireland, and the new 
National Independent Safeguarding Board in Wales 
should not be overlooked; with duties to promote the 
effectiveness of LSCBs and SCRs, they are in a prime 
position to take the lead on an initiative to improve 
the usefulness of learning derived from SCRs. 
In the ‘Child BT’ overview report, it is stated that the 
police recovered a child’s feeding cup in the yard of 
the family home, which was later found to contain 
methadone. The second post-mortem revealed the 
underlying cause of death as methadone poisoning. 
The mother explained that methadone was stored in 
various receptacles in the house because she was 
selling it. A discussion of ‘significant events and 
102  DCSF (2008) Understanding Serious Case Reviews and their Impact: a biennial analysis of serious case reviews between 2005 and 2007
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authorities in England and Wales were contacted 
with information on the training, and requested to 
submit an expression of interest should they wish to 
participate. By October 2015, 34 local authorities had 
registered their interest. The 15 local authorities to 
which Adfam will deliver training in 2015 were selected 
based on two criteria: whether they had experienced 
a child ingestion of OST medications locally, and 
numbers of parents in receipt of a prescribing 
intervention. 
The aim of the training is to develop a blueprint to 
enhance local practice regarding safeguarding the 
children of OST-prescribed service users, based on 
the learning from national SCRs. It is designed to help 
practitioners:
 — Make appropriate risk assessments for children 
living with an adult prescribed OST drugs
 — Consider the evidence base on the impact of 
parental substance use generally
 — Conduct improved welfare checks for children, 
including signs of drug ingestion
 — Create and implement a shared safety plan to 
enhance local practice, and
 — Identify mechanisms to establish inter-agency 
partnerships and future joint-working
The impact of the training and the extent to which 
it improves local practice is largely dependent on 
multi-agency attendance from a mix of frontline 
professionals and managers, and a continued effort 
by different local services to work together and share 
information to identify risk and effectively implement 
adequate safeguards. 
Since the publication of the original report, Adfam has 
continued to work to raise awareness of the issue, and 
help share best practice, so that the risks to children 
posed by OST drugs are minimised. This section sets 
out Adfam’s work over the past year to improve local 
and national responses to the issue. 
Best practice training for local authorities
As well as meeting with and presenting to hundreds 
of practitioners and stakeholders in the children’s, 
health, social care and drug sectors to disseminate and 
publicise the issue and the report’s findings, Adfam 
also developed a multi-agency training package for 
local authorities that want to improve local practice 
and joint-working. Throughout September 2015, 
Adfam worked with experienced trainers to deliver this 
training to four pilot areas. A total of 58 practitioners 
from a range of services were trained, including 
treatment providers, children’s social care, health 
visitors, prescribers, the police and probation, and 
an evaluation revealed positive results. Practitioners 
commented on the invaluable opportunity provided 
by the training to build relationships with colleagues 
from other agencies, and to share experiences 
and knowledge. For example, a health practitioner 
stated, ‘I thoroughly enjoyed meeting other services 
and understanding each other’s roles better.’ Other 
feedback suggested that attendees welcomed practical 
information, such as how to recognise the signs of 
OST ingestion in children, and the impact of parental 
substance use generally. 
This training will be delivered to a further 15 local 
authorities across the country before 2016. Local 
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 — A wider social and whole family approach to 
treatment should be adopted by all agencies: 
working with the family is everyone’s business. 
Adfam suggested a sub-section be incorporated 
into the guidance dealing specifically with the 
issue of professional competency, given the 
evidence gathered by Adfam showing that there 
is significant variation in professional skills and 
attitudes
 — Risks to children should be the primary 
consideration when deciding which drug to 
prescribe and whether to allow take-home doses. 
Adfam is of the opinion that the current wording 
of the guidelines needs to be strengthened and 
elaborated; to stress the toxicity of methadone 
to children in even very small doses, to ensure 
that children are the primary consideration in 
any assessment, to encourage communication 
between the prescriber and dispensing 
pharmacist about safe storage and use of 
medications, to emphasise the necessity of input 
from other professionals and, in particular, the 
role of professionals visiting the home
 — Current guidelines insufficiently emphasise 
and prioritise the risk of methadone overdose 
to children. The current statement that ‘if both 
[methadone and buprenorphine] appear equally 
suitable, methadone should be prescribed as 
the first choice,’ has potentially led to the use of 
methadone as a ‘default’ option by clinicians. In 
its submission, Adfam asserted that both drugs 
may in fact not be equally suitable for clients who 
could pose a risk to children by storing or using 
the medication inappropriately
Wider policy influencing
As noted earlier, following the publication of the 
original report, Adfam presented the findings and 
recommendations to hundreds of professionals in 
the health, social care and drug sectors, and met 
with a range of organisations and individuals to 
raise awareness of the issues and embed the report’s 
recommendations.103 In terms of wider efforts to 
highlight the issues identified in the original report, 
Adfam responded to consultations by the Department 
of Health (DH) and the Care Quality Commission 
(CQC). 
The DH invited feedback on the ‘Orange Book’ 
clinical guidelines,104 to which Adfam responded105 
in September 2014. The guidelines are rightly 
considered by the drug treatment sector, alongside 
NICE guidance, as the cornerstone of evidence-based 
practice in drug treatment. Adfam, in its submission, 
detailed how families can best be included in the 
guidelines, how their role can be harnessed to 
support service users through their treatment journey 
and how children can be effectively safeguarded from 
the risks of OST medications. The following priorities 
were highlighted:
 — Assessments of risk should include enquiries 
about contact with children, as well as children 
living with or dependent on the service user, 
with particular attention paid to males. Adfam 
also submitted that the safety of prescribed 
medication should form an important element of 
the care or treatment plan
103  A list of agencies and individuals presented to and met with is included in Section One
104  Department of Health (2007) Drug Misuse and Dependence: UK Guidelines on Clinical 
Practice
105  Available to download at: http://www.adfam.org.uk/cms/docs/Adfam_Response_-_
Orange_Book,_Clinical_Guidelines_Review.pdf (pdf)
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Adfam submitted a response106 to the CQC’s proposals 
for inspecting and rating providers of substance 
misuse services in March 2015, and again highlighted 
the issues around child OST ingestion and the 
necessary safeguarding implications, including:
 — In order to assess the ‘safe management of 
medicines’ – one of the CQC’s key lines of enquiry 
– including prescribing, recording, handling, 
storage, safe administration and disposal, 
attention must be paid to the risks posed by take-
home prescriptions to children, especially drugs 
used in OST
 — In inspecting and rating a service’s safety, it is 
advisable to gather information on the policies 
and procedures in place relating to OST, take-
home medications and assessing risks to children
 — A service rated ‘outstanding’ on its safety 
indicators should have robust policies and 
procedures in place, which recognise and 
prioritise risks to children posed by OST 
medications – without which, a service should 
not be called ‘outstanding.’
Adfam hopes that the multi-agency training 
programme and recommendations to both the Care 
Quality Commission and the Department of Health 
consultations will result in a more coordinated 
response to minimize the harm to children caused by 
OST medications.
 — The guidance states that even where there are 
concerns about the safety of medicines stored 
in the home and risks to children, ‘take-home 
doses might be permitted but the dose taken 
home limited by dispensing frequency.’ Adfam 
suggested that this be wholly removed, given 
that it potentially devalues the importance 
of children’s safety. Further guidance on the 
processes governing progression from supervised 
consumption to take-home medication was also 
requested. 
Throughout the response, Adfam continually 
emphasised the importance of safe storage and 
checks on storage arrangements. The need for inter-
agency cooperation was similarly accentuated, and 
the utility of home visits articulated. The revised 
guidelines are expected in 2016.
106  Available to download at: http://www.adfam.org.uk/cms/docs/Adfam_-_CQC_
How_we_regulate_specialist_substance_misuse_services_consultation_response_-_
March_2015_FINAL.pdf (pdf)
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methadone and buprenorphine is a welcome 
addition to the debate, and should encourage a 
wider discussion of their relative benefits when 
prescribing to clients with children, including a 
review of current guidance to ensure it sufficiently 
highlights the particular risks of methadone to 
children. The number of child (and adult) deaths 
attributed to buprenorphine is significantly less 
than those to methadone, and available evidence 
suggests that buprenorphine presents less 
mortality risk. On this basis, it seems that the 
wider prescribing of buprenorphine to parents 
in treatment, when combined with adequate 
safeguards, such as safe storage, robust risk-
assessments (reflected in the prescribing and 
dispensing regimes), good inter-agency cooperation, 
efficient information sharing and a curious and 
challenging workforce, could contribute to the 
effective management and minimisation of the 
dangers of OST to children. As Lord Laming stated, 
‘Doing the basic things well keeps children safe.’107 
We cannot say with any certainty the degree to 
which any or all of these measures reduce risk, but 
this report presents strategies and examples of 
practice for practitioners to improve their ways of 
working to this end.
In gathering evidence of local changes, with a view 
to identifying and highlighting good practice, as 
well as gaps, over 25 local authorities were asked 
to submit evidence. Eleven respondents provided a 
variety of materials. Whilst local practice inevitably 
differs in tackling the issue, a number of key points 
were highlighted. Despite these promising, albeit 
This report sought to build upon the knowledge 
and learning of the original report, provide updated 
information and statistics, and assess the extent 
to which the recommendations of the original 
report and those of SCRs have been implemented. 
It is hoped that it will further contribute to the 
ongoing debate about OST and the implications 
for safeguarding policies and practice, and inspire 
meaningful and sustainable change. However, 
Adfam is clear that these discussions should not 
endanger the rightful place of prescribed OST 
medications in a recovery-orientated treatment 
system. The unmistakeable dangers of OST drugs 
to children must be explored without fuelling 
an unhelpful debate over the use of substitute 
prescribing in treating drug dependencies – the 
evidence in support of which has long been well-
established.
Since 2003, at least 328 children in England 
have been admitted to hospital with methadone 
poisoning. Between 2003 and 2013, at least 110 
children in the UK have died from methadone (107) 
and buprenorphine (3) poisoning. These data provide 
a much more accurate reflection of the scale of child 
ingestions of OST medications, and it is hoped that 
this will inspire a nationally-driven, coordinated 
response to tackle the issue. However, the mortality 
data is limited in what it can tell us about the 
circumstances of these deaths and, as a result, is of 
limited help in informing a coherent and effective 
policy mandate to minimise this risk to children. 
Evidence relating to the comparative safety of 
107  Lord Laming (2003) The Victoria Climbié Inquiry Report
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lessons for good practice. 
The Department for Education or Ofsted would be 
best placed to carry out this work.
New Recommendation: These biennial analyses 
should be disseminated to relevant practitioners and 
organisations. The national bodies – the Association 
of Independent LSCBs in England, the National 
Independent Safeguarding Board in Wales, the 
Scottish Child Protection Committee Chairs Forum 
and the Safeguarding Board for Northern Ireland – 
are in a prime position to both collate and analyse 
reviews and disseminate learning to the Local 
Safeguarding Children Boards.
Issue 2: The effectiveness of SCRs 
Original Recommendation: A representative from 
a drug treatment agency should be present on all 
Local Safeguarding Children Boards, to ensure 
that lessons relating to parental substance use are 
properly prioritised locally. Drug treatment services 
should also be represented on the review panel for 
any serious case reviews where the parents’ drug or 
alcohol use is relevant.
Issue 3: A lack of publicly available 
information and data around the issue 
Original Recommendation: Data should be 
collected centrally on the number of parents 
prescribed different OST drugs, and on which 
supervision regimes. It would also be beneficial to 
analyse whether these cases involved accidental 
ingestion by the child or intentional administration 
by the parent(s). Collection of this data should be 
the responsibility of Public Health England (PHE) or 
the Department of Health.
few, examples of local practice, the SCRs discussed 
above show that children are still dying and coming 
to serious harm after ingesting OST medications. 
Moreover, the similarity between the facts and 
recommendations of the SCRs considered in both 
this report and the original suggests that national 
learning is still lacking, and more should be done to 
minimise this risk to children. In addition, national 
recognition and awareness of the issue is below 
what it should be considering the scale of the 
problem. 
Not enough is being done to manage risk and reduce 
the number of child ingestions of medications used 
in the treatment of opioid dependence. The original 
report identified a number of key issues, and this 
report has confirmed their continuing relevance. As 
such, the main issues are set out below, together 
with the associated recommendations from the 
original report; amended to reflect whether they 
have been followed up. New recommendations are 
also made in light of new evidence. 
Issue 1: National learning from SCRs is 
lacking
Original Recommendation: Full overview reports 
of Serious Case Reviews involving OST drugs should 
be centrally analysed by Government-appointed 
researchers. Further research into these cases 
and the learning from them, including an analysis 
of what was changed at the local level and how 
this was evaluated, is warranted. There should 
also be a commitment to collect and review any 
OST cases across the UK biennially and examine 
the key learning points for practitioners, the 
implementation of new recommendations and any 
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Issue 4: A lack of awareness of the dangers 
of OST to children and professional 
competency
Original Recommendation: Training for drug 
services, pharmacies and GPs must highlight the 
dangers of OST medicines to children. Workers 
should also be able to address the intentional 
administration of OST medicines and other drugs 
to children with service users and take an active 
role in promoting positive parenting practices. Such 
developments dovetail with the ongoing focus on 
healthy scepticism and professional challenge. 
Other professionals working with vulnerable 
families, especially those undertaking home visits, 
also need to be alert and vigilant about the dangers 
of OST drugs.
New Recommendations: Home visits should 
be regularly conducted to ensure a whole-family 
approach, check on storage arrangements and 
identify the family’s needs and other risk factors. 
The role of health visiting teams must be recognised 
by local partners, and health visitors should 
receive training and guidance on working with 
families where parental substance use is a factor. 
Routine notification procedures for professionals 
working with the family are conducive to effective 
information-sharing, early intervention and 
prevention. However, further research should be 
conducted to clarify issues of consent when sharing 
personal information.
Drug services and commissioners should ensure a 
‘child focus,’ through its explicit inclusion in service 
level agreements and service specifications. 
New Recommendations: Hospitalisation data held 
by the Health and Social Care Information Centre, 
and mortality statistics held by the respective three 
national bodies (the Office for National Statistics, 
National Records of Scotland and Northern Ireland 
Statistics and Research Agency) should be centrally 
monitored to identify emerging patterns and trends. 
This should be the responsibility of PHE or the 
Department of Health.
The data should contain information on the 
circumstances surrounding the death, including 
individual characteristics, how the drug was 
obtained (i.e. to whom it was prescribed) 
and whether the case was one of suspected 
accidental ingestion by the child or of intentional 
administration by the parent(s). This data should be 
published biennially. The development of national 
standards for reporting child ingestions of OST 
medications and clarification on SCR thresholds is 
also warranted.
Further research into the circumstances by which 
adolescents (as opposed to very young children) 
come to ingest OST drugs is needed, in light of the 
evidence from mortality statistics. Research into 
how and why parents may be administering drugs to 
their children is also warranted.
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Issue 6: We know that a single, isolated 
incident can be fatal. Safety measures 
should reflect this
Original Recommendation: Safe storage boxes 
should be provided to all treatment clients in receipt 
of OST, if they ever take any of their prescription 
home. There must also be consistent checks on 
storage arrangements, and information about the 
dangers of OST should be provided on an ongoing 
basis. Systems should be in place between different 
local agencies to distribute knowledge of, and 
responsibility for, monitoring and ensuring safe 
storage, including the sharing of safety plans agreed 
with the service user.
New Recommendation: Further research and 
clarification of guidelines on the use of naloxone in 
cases of child ingestions is warranted. 
Issue 5: Despite clinical guidelines, 
safeguarding concerns are not sufficiently 
prioritised in reality 
Original Recommendation: Guidance on the 
implementation of NICE, specifically Technology 
Appraisal 114, must reemphasise safeguarding 
children as a primary factor in making and reviewing 
decisions about OST, including which drug to 
prescribe and whether to permit take-home doses. 
This would be the responsibility of Public Health 
England or the Department of Health. There is also a 
role for the Secretary of State for Health in ensuring 
that NICE is implemented at the local level.
New Recommendation: Further research into the 
relative safety of buprenorphine and methadone 
in the context of child ingestions specifically is 
warranted. Clinical guidelines should also seek to 
clarify the circumstances under which both drugs 
will not be considered ‘equally suitable’, in light of 
evidence on the respective safety of methadone and 
buprenorphine. 
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